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Abstract
The better understanding of the diverse mechanisms leading to the hemorrhagic transformation of an ischemic stroke is the crucial point in the prevention of this 
altogether common phenomenon. The different individual risk factors include the anatomical variability of collateral blood supply, age, genetics, body weight, etiology 
of the occlusion, side of the occluded vessel, renal status, stroke severity, history of high serum glucose or hypertension and hypertension or hyperglycemia at the 
onset of the stroke, ferritin level, INR, antiplatelet usage or the platelet count etc. All these might contribute to the process of hemorrhagic transformation. These risk 
factors have been identified by retrospective epidemiological studies and are useful to identify patients who are at high risk for hemorrhagic conversion and help the 
decision between conservative, thrombolytic or more advanced treatments such as thrombectomy. The modulations of potential molecular targets participating in the 
process seem to be promising in animal models, but human trials are lacking the breakthrough success so far, both in extending the time frame of the thrombolysis 
and in replacing the recombinant tissue plasminogen activator (rtPA) as thrombolytic agent. 
So far, the careful preselection of patients eligible for thrombolytic therapy is the best way to prevent hemorrhagic transformation. The intensive research in the field 
revealing small but important molecular details are continuously contributing to the better understanding of hemorrhagic transformation with the intention of finding 
new agents that co-administrated to the rtPA or completely replacing that could decrease the risk of secondary bleeding.
The aim of this review is to give comprehensive insight into the process of hemorrhagic transformation of ischemic stroke, starting with basic overview of the 
penumbra concept and the collateral supply followed by discussion of the recanalisation-reperfusion-hemorrhagic transformation process after vessel occlusion also 
highlighting the importance of timing and ratio of recanalisation spontaneously and in case of thrombolytic agent administration. We overview the risk factors of 
hemorrhagic transformation, which may be helpful to physicians to identify high risk patients before rtPA administration. The last part of the work is dealing with 
future therapeutic possibilities based on the so far revealed molecular mechanisms of hemorrhagic transformation. 
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Abbreviations
rtPA: recombinant tissue plasminogen activator, BBB: blood–brain 
barrier, CT: computed tomography, HI-1 - hemorrhagic infarction 1, 
HI-2: hemorrhagic infarction 2, PH-1: parenchymal hematoma 1, PH-2: 
parenchymal hematoma 2, CS: collateral status, MCA: middle cerebral 
artery, ACA: anterior cerebral artery, ECASS: European Cooperative 
Acute Stroke Study, MCAO: middle cerebral artery occlusion, DWI: 
diffusion weighted imaging, PWI: perfusion weighted imaging, MMP: 
matrix metalloproteinas, PDGF: platelet-derived growth factor, 
PDGFR: platelet-derived growth factor receptor, HSP70: heat shock 
protein 70, CBV: cerebral blood volume, NCCT: non contrast CT, MTT 
ASPECTS: mean transit time Alberta Stroke Program Early CT Score, 
NOX: NADPH oxidase 1, NIHSS: National Institutes of Health Stroke 
Scale, AHT: asymptomatic hemorrhagic transformation, ROS: reactive 
oxygen species, DM: diabetes mellitus, NADPH oxidase: Nicotinamide 
adenine dinucleotide phosphate oxidase, NO: nitrogen monoxide, 
HMGB1: high mobility group box 1, VEGF: vascular endothelial 
growth factor, MT-MMP: membrane-type matrix metalloprotease, 
NSE: Neuron specific enolase, CSF: cerebrospinal fluid, OCLN: 
occludin, CLDN5: claudin 5, ZO-1: zona occludens 1, FDP: fibrin 
degradation products, APC: Activated protein C, EPCR, endothelial 
cell protein C receptor, PAI-1: plasminogen activator inhibitor 1, 
TAFI: thrombin-activatable fibrinolysis inhibitor, PAI-1: Plasminogen 
activator inhibitor-1, VAP-1: Vascular adhesion protein-1, SSAO: 
semicarbazide-sensitive amine oxidase, 15d-PGJ2: 15-Deoxy-Delta-
12,14-prostaglandin J2, PPARγ: peroxisome proliferator-activated 
receptor gamma, A2M: alfa-2-macroglobulin, ASPECTS score: 
Alberta stroke program early CT score, HARM: hyperintense Acute 
Reperfusion Marker, ADC: apparent diffusion coefficient, FITC 
albumin: fluorescein isothiocyanate albumin, MAP2: anti microtubule 
associated protein, SOD1: superoxide dismutase 1, NOX2: nicotinamide 
adenine dinucleotide phosphate oxidase, MARCH7: membrane 
associated ring CH 7, EGFR: endothelial growth factor receptor, 
MAP kinase: mitogen-activated protein kinase, TGF-ß: Transforming 
growth factor- ß, IRAK3: interleukin-1 receptor associated kinase 3, 
INP5P: inozitol phosphate-5-phoshpatase, LRP: lipoprotein receptor 
protein, GM-CSF: Granulocyte macrophage colony-stimulating factor, 
TIPM: tissue inhibitors of metalloproteinases, CCR2: C-C chemokine 
receptor type 2, CNS: central nervous system, MO/MP activation: 
monocyte/macrophage activation, COX: Cyclooxygenase, tMCAO: 
transient middle cerebral artery occlusion, TLR4: toll-like receptor 
4, EPC: endothelial progenitor cell, SFK: SRC family kinase, GRE: 
Gradient-recalled echo, Bcl-2 gene: B-cell lymphoma 2 gene, AQP4: 
Aquaporin 4, TEER: transendothelial electrical resistance, TJ: tight 
junction, NPD-1: neuroprotectin D1, DHA: docosahexaenoic acid, 
PUFA: polyunsaturated fatty acid, ICAM-1: intercellular adhesion 
molecule-1, GSK-3β: Glycogen synthase kinase 3β, COMP: cartilage 
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With the aim to assess the rate and influencing factors on the 
recanalisation and reperfusion rate 381 patients with large-vessel 
occlusion was investigated. The patient group involved ones treated 
with rtPA or treated conservatively. Partial or complete recanalisation 
was achieved in 121 out of 210 (58%) patients after intravenous rtPA 
administration. The recanalisation success was more likely if the patient 
had atrial fibrillation [4] - maybe because cardioembolic clots consists 
more fibrin and are more likely to reopen by plasmin proteolysis 
than thrombosis of an atherosclerotic plaque – or in absence of early 
ischemic changes on CT as sign of better collaterals or smaller core. The 
significant extracranial (EC) stenosis or occlusion correlated negatively 
with the recanalisation success, since the decreased blood flow towards 
the clot is accompanied by decreased amount of rtPA reaching the 
clot and in addition the clot washout is weaker as well. In non-rtPA 
treated cases the spontaneous recanalisation rate was only 37% and was 
positively associated with history of hypercholesterinaemia, proximal 
occlusion, and inversely connected with decreased consciousness, 
extracranial or basilar artery pathology. It is important to mention 
that presence of recanalisation was assessed 24 hours after onset, and 
it is well known that recanalisation can occur even a week after onset 
[5]. Based on earlier studies it seems to be obvious that success and 
the benefit of reperfusion depends on the timing, the core size, the 
penumbra/core ratio and the collateral supply [6-11]. Further studies 
reported that milder baseline stroke deficits, elevated systolic blood 
pressures, normal glucose values, smoking history, absence of atrial 
fibrillation, distal vessel occlusion, and thrombus length positively 
predicts post-thrombolytic recanalisation. Considering these risk 
factors in individual cases, perhaps patients with smaller chance 
for reperfusion/recanalisation could benefit from more aggressive 
interventions, such as intra-arterial fibrinolysis [12-18].
Ratio and timing of spontaneous recanalisation
Reperfusion and recanalisation can occur spontaneously up to 
several weeks after stroke onset, though according to the time is brain 
concept, it is irrelevant regarding the clinical outcome unless it happens 
within several hours after onset [19]. To demonstrate the dynamic 
of the spontaneous recanalisation a study investigated the timing of 
recanalisation after cardioembolic stroke. Out of 53 patients 10 showed 
spontaneous recanalisation in the first 6 hours, without HT. 19 patients 
showed recanalisation between 6-12 hours, with a HT rate of 60%. 15 
patients showed no recanalisation in the first 48 hours, and accordingly 
the HT was lower, just 20%. All of the 3 patients with recanalisation 
between 24-48 hours showed HT. These results imply that reperfusion 
after 6 hours from occlusion is an independent predictor of HT. 
Another sub-analysis of this very study showed, that HI-1, HI-2, PH-1 
were not related neither to early nor to 3 month outcome. Only PH-2 
was associated with worse clinical outcome. In this study, all PH-2 
occurred in the 6-12 h interval [20,21] (Figure 1 and 2).
Timing of HT after recanalisation
In order to, get more detailed picture of the underlying mechanism 
of the HT, spontaneously hypertensive rats were used to assess the 
dynamic of the reperfusion induced HT and lesion evolution. Due to 
the spontaneous hypertension of the rat models, 100% of the animals 
suffered HT. The results show that after 30 minutes MCA occlusion by 
day one 3/13, by day two 6/13, by day three 11/13 by day four 12/13, 
by day seven 13/13 animals presented HT. It means that the 92.3% of 
HT occurred within the first 4 day. The lesion volume increased from 
day 1 to day 2 as a result of vasogenic edema and decreased to its 
original size between day 4 and 7. The hemorrhage volume increased 
progressively, which meant an ECASS (European Cooperative Acute 
Stroke Study) class (HI-1, HI-2, PH-1, PH-2) evolution in 61,5% of the 
oligomeric matrix protein, TXNIP: thioredoxin-interacting protein, 
SMTP: Stachybotrys microspora triprenyl phenol, GLUT-1: Glucose 
transporter 1
Introduction
The hemorrhagic transformation (HT) is a complication of ischemic 
stroke. In the clinical practice, it is indeed regarded as a complication, 
since it is the most feared consequence of thrombolytic therapy, 
although altogether the hemorrhagic transformation occurs quite often 
after ischemic stroke, between 10-40% depending on the individual 
influencing factors, suggesting that it is rather part of a normal process. 
We have to make difference between 2 main histological categories. 
The hemorrhagic infarct, which is actually petechial bleeding accounts 
for 89% of all HTs and has no effect on the prognosis or shows positive 
association with long term clinical outcome, since it is considered as 
sign of recanalisation. However, the parenchymal hematoma, 11% of 
all HTs, is definitely a complication, due to its detrimental effect on the 
prognosis. 
Thrombolysis was the only available causal treatment for 
stoke patients until 2015, when the FDA approved the mechanical 
thrombectomy as effective treatment. Depending of various 
circumstances, unfortunately only less than 5-20% of all stroke patients 
are eligible for rtPA (recombinant tissue plasminogen activator) 
treatment, due to the narrow time window of the administration. 
Out of the time window, the risk of PH is getting so high, that risks 
overwhelm the benefits. 
Most of the researches today are making huge efforts to achieve the 
extension of the time frame by preventing HT via BBB (blood–brain 
barrier) protection, recognizing the importance of complementary 
therapies beside rtPA. The better understanding of the underlying 
mechanisms and risk factors of this complex process will hopefully 
lead to more precise preselection of patients for thrombolytic therapy, 
newer therapeutic targets and to newer possibilities in the stroke 
management.
Recanalization and reperfusion
Reperfusion means restoration of the downstream capillary blood 
flow by recanalisation of the occluded vessel. The reperfusion can occur 
in anterograde way by spontaneous or therapeutic recanalisation or in 
retrograde way via collateral circulation. The aim of the recanalisation 
therapies (rtPA, intra-arterial fibrinolysis, neurothrombectomy) is the 
restoration of anterograde blood flow in the penumbra, including the 
microcirculation. Recanalisation and reperfusion have been regarded 
as one unit, but according the novel observations there are only a 
modest connection between them, indicating that recanalisation and 
reperfusion should not be used as synonyms. These observations can 
be explained with the no reflow phenomenon, which describes the 
situation where after a successful recanalisation of the occluded big 
vessel, in consequence of ischemia induced microvascular endothelium 
activation and microvascular clot formation, reperfusion at least partly 
will not occur. On the other hand reperfusion can occur without 
recanalisation as a result of retrograde filling due to better collateral 
circulation, although this process is hugely depending on the site of 
the occlusion, whereas a proximal occlusion is accompanied by more 
impaired collateral circulation [1]. Reperfusion and recanalisation is 
regarded to be a dynamic process that occurs gradually over hours with 
periods of partial reperfusion and the patency of the occluded vessel 
fluctuates during the recanalisation process [2,3].
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animals from a milder into a more severe category. This result suggests 
that HT is a quite dynamic process, which can last up to a week. HI-1 
occurred most frequently by the periphery of the lesion and HI-2, PH-
1, PH-2 were located rather central in the infracted area. Just PH-2 
was associated with clinical symptoms. Only PH-2 was associated with 
worse clinical outcome.1 As for the dynamic of the BBB breakdown, 
initial BBB disruption occurred in 3-4 h following the 2h MCAO in rat 
models with a peak at the 5th hour. Surprisingly, at 48h after MCAO, a 
delayed, more profound and expanded BBB permeability increase was 
observed. The supposed molecular background of this observation is 
detailed in the X/5 paragraph [22]. The vast majority of HT after rtPA 
treatment occurs within the first 24 hours [23].
Ratio and timing of recanalisation with rtPA
A study from 2013 reported, that the hyperdense artery sign as a 
reliable indicator of occlusion disappears only in 55% of the patients 
Figure 2. 1. tPA binds to fibrin on the surface of the clot. 2. Activates fibrin-bound 
plasminogen. 3. Plasmin is cleaved from the plasminogen associated with the fibrin. 4. 
Fibrin molecules are broken apart by the plasmin and the clot dissolves. Fibrin degradation 
products are released (modified from http://www.cvpharmacology.com/thrombolytic/
thrombolytic). 
Hemorrhagic transformation
Parenchimal hematoma
Hemorrhagic infarction
Figure 1. ECASS classification of HT (HI-1, HI-2, PH-1, PH-2).Theleft coloumn shows gradient-recalled echo images. Bleeding is hypointense (white arrows). The right coloumn shows 
images of hematoxylin-eosin–stained tissue. Bleeds are red; surrounding tissue is blue (nuclei) or pink (cytoplasm). HI-1 is a petechial bleeding occurring most frequently along the lesion 
periphery. HI-2: confluent petechial hemorrhage, located mainly int he infarct core. PH-1: real hematoma (<30% lesion volume) with or without mild space occupying effect . PH-2: 
hematoma (>30% lesion volume) with significant space occupying effect and perihematomal edema [21].
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after rtPA administration, suggesting a 55% recanalisation rate of 
thrombolysis [24]. The analysis of 5324 cases, where recanalisation was 
defined by CT or MR angiography as the resolution of dense artery 
sign, reports that out of 5324 cases 2592 (48,7%) showed recanalisation 
and 2412 (45,3%) not.
The best 3 month outcome could be expected in the patient 
group with 2 hours post treatment neurological improvement (NI) 
accompanied by vessel recanalisation. Both recanalisation and early 
NI are independent predictors of good 3 month functional outcome. 
After that, the patient group with neurological improvement in spite 
of persistent occlusion presented the second best prognostic prospects. 
Patients without neurological improvement despite recanalisation 
and the group without improvement and without recanalisation 
delivered the worst prognosis. Based on these findings a further, 
more intensive intervention, such as intra-arterial thrombolysis 
or neurothrombectomy warrants to be considered even in case 
of neurological improvement after rtPA, when reperfusion is not 
occurred, or the result is not satisfactory, despite the fact that the recent 
stoke treatment protocol declares clearly, that early NI is an exclusion 
criteria of further intravenous (IV) or intra-arterial (IA) thrombolysis, 
since early NI is an accepted sign of recanalisation after IVT, and has 
association with good 3 month prospects. 
This very study supports the previous results of earlier studies, 
stating that even delayed recanalisation with mechanical thrombectomy 
or with other methods is related to better 3 month functional outcome 
[25]. For instance this earlier study ascertained that delayed (>6h) 
recanalisation has a favorable outcome regarding the DWI lesion 
expansion and can save peripheral cortical areas, in comparison 
to patients without recanalisation, implying that the collateral 
circulation may remain sufficient during a longer time interval [26]. 
Another systematic review and meta-analysis from 2012 support the 
known fact about rtPA treatment, the earlier the administration the 
better the outcome, although a subgroup of patients with individual 
characteristics and risk factors could definitely benefit from an 
extended rtPA administration interval [27].
As for the recanalisation rate and time course after intravenous 
thrombolysis, the following implies that the recanalisation itself is a 
dynamic process and the patency of the occluded vessel might fluctuate 
during the first 24 hours after treatment. Of 160 patients treated with 
rtPA, 82 patients (51.3%) showed recanalisation in the first 2 hours after 
rtPA administration monitored by transcranial Doppler. From these 
82 patients 67 (81.7%) presented persistent recanalisation, which was 
investigated at 24 hours after rtPA treatment by computed tomographic 
angiography (CTA). From the original 160 cases altogether 84 (52.5%) 
showed recanalisation by the CTA at 24 hours regardless of the early 
recanalisation. As for the 3-month outcome the results imply that all 
kind of  recanalisation in the first 24 hours is strongly associated with 
better outcome at 3 months [3].
Impact of rtPA on HT
Administered rtPA in the same way like endogen rtPA increases 
the MMP-2 [28], MMP-3 [29], MMP-9 levels in the brain [30]. It binds 
to protease activated receptor 1 on endothelial cells activating NF-
κB pathway altering the vascular permeability and raising the MMP-
9 level. Furthermore, rtPA due to its proteolytic activity removes an 
amino-terminal CUB domain from PDGF-CC homodimer causing 
its activation. The activated PDGF-CC than triggers PDGFR-α surface 
tyrosine kinase in the neurovascular unit, especially on astrocyte end 
feet, since it expresses a great number of PDGFR-α, increasing the BBB 
leakage [31-33].
Active rtPA injected in the cerebrospinal fluid of non-ischemic 
mice caused increased permeability of the BBB however administered 
intravenously was not followed by BBB leakage, suggesting that rtPA 
perform its negative effect on the abluminal side of the neurovascular unit. 
The usage of Imatinib, a non specific tyrosine kinase inhibitor, co-
administered to rtPA was associated with decreased BBB permeability, 
significantly smaller infarct size and lower HT rate, implying that 
imatinib interferes with PDGF signaling and PDFG signaling interferes 
with the BBB integrity. 
rtPA is also capable of binding to the lipoprotein receptor protein 
on endothelial cells, increasing the emission of MMP-3 and MMP-9 
[28,30,34]. Last but not least rtPA can support the degranulation of 
neutrophils into the blood, increasing the blood MMP-9 level [35]. 
This recent study investigated the time dependent effect of rtPA 
after 90min transient MCAO on spontaneously hypertensive rats. The 
first group of rats got no rtPA, the second got rtPA at the time of the 
recanalisation, and the third got rtPA 4 hours after recanalisation. MR 
imaging was performed 4 times, first during the occlusion and 3,6,24 
hours after reperfusion. The BBB permeability on MR was examined as 
well, to assess the dynamic of the BBB opening. During the occlusion 
the permeability values were low in all groups. On the 3h MR image 
the second group presented the highest permeability values, but on the 
6 h image the third group showed the highest BBB breakdown. On the 
24h image the values were relatively decreased in comparison to earlier 
time points, but were even higher than during the occlusion. According 
to the observations above the highest HT (36,4%) and mortality rate 
(63,6%) was found in case of delayed rtPA administration. HT occurred 
mostly 6 h after reperfusion, when BBB permeability values were the 
highest. In the second group both the HT rate and the mortality was 
10%. In the first group there was no observed HT or death [36]. These 
results are in agreement with other studies [37,38].
Penumbra
Penumbra is the so-called tissue at risk. This area is thought to 
be functionally silent and metabolically metastable but potentially 
salvageable if recanalisation occurs in a short period of time, and a 
full recovery can be expected. The size of the penumbra is individually 
different as a consequence of the hugely individual functional 
performance of the collateral system [39] (Figures 3-5).
Approximately 8-12 hours pass by from the onset of the ischemic 
stroke till the infarcted area reaches its final size. There are several 
individual factors, such as site of vessel occlusion, degree of ischemic 
preconditioning, richness of collaterals, systemic blood pressure, blood 
volume, serum glucose, that influence this process. In general, the bigger 
the penumbra the bigger the potential benefit of rtPA administration.
The usage of rtPA has a recommended 4,5-hour time frame after 
stroke onset. This limit is necessary because of the ischemia induced 
BBB defect, which gets more severe in the course of time, resulting in an 
increased ratio for HT, especially for PH2. (parenchymal hematoma). 
However the „tissue at risk” could be salvaged between 8-12 hours, 
individually after stroke onset. That is why the researches today are 
pointed at the rtPA time window extension through BBB protection or 
improving the newer recanalisation methods like neurothrombectomy 
or trying to find alternatives to rtPA [19].
Collateral flow
Collateral flow system contributes enormously to the clinical 
outcome and tissue fate after an ischemic stroke event. In case of MCA 
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Figure 3. On the left side we have a diffusion MR image indicating the area with irreversible changes (dead issue).In the middle there is a large area of vital but hypoperfused tissue. On 
the right the diffusion-perfusion mismatch is indicated in blue. This is the tissue at risk that could be potentially saved with therapy. (modified from http://www.radiologyassistant.nl/en/
p483910a4b6f14/brain-ischemia-imaging-in-acute-stroke.html)
Figure 4. The four subtypes of hemorrhagic transformation (CT imaging) [253].
(middle cerebral artery) occlusion collateral blood flow is supplied 
from the ACA (anterior cerebral artery) through the circle of Willis 
and through leptomeningeal anastomoses between cortical branches of 
MCA and ACA, and via extra and intracranial communication. Study 
results on rats with artificial induced transient ischemia showed strong 
correlation between the extent of collaterals and the ischemic core size. 
The molecular penumbra can be visualized by the presence of HSP70 
Heat Shock Protein in neurons, which protein is the end product of 
natural defending pathways protecting the cell from further ischemic 
damage. The degree of collateral supply was inversely associated 
with molecular penumbra size and with final core size, which means 
the better the collateral supply the bigger the uninjured area. Acute 
MRI-defined penumbra is expected to be larger than molecular 
penumbra after 24 h of reperfusion due to the progressive recruitment 
of penumbra into the infarct core. The topographical mapping of the 
molecular penumbra revealed multiple patchy areas with irregular 
distribution and was not limited to the perilesional zone. Though, the 
finally infarcted area invariably consisted in one single lesion [39].
Better the collateral status, the bigger the penumbra and the 
smaller the core. That means more potentially salvageable tissue when 
the patient undergoes rtPA treatment. The better collateral status is 
associated with better recanalisation grade as well. Worse collateral 
status (CS) means bigger risk for worsening symptoms, increased 
severity and altogether worse clinical outcome. The penumbra is a 
mismatch between the diffusion CT image and perfusion CT image, 
so bigger the area with perfusion but without diffusion means bigger 
penumbra. Therefore, worse state of pial collateral system is associated 
with larger diffusion abnormality. The side of the clot and the CS 
are both independent factors of the clinical outcome among patients 
treated with rtPA. Favorable CBV (cerebral blood volume), NCCT 
(non contrast CT), and MTT ASPECTS (mean transit time Alberta 
Stroke Program Early CT Score) at arrival and favorable 3 month 
outcome were associated with good collateral status. Poor collateral 
status is associated with proximal occlusion and low NIHSS (National 
Institutes of Health Stroke Scale) on admission, but the distal occlusion 
is not predictor of good collaterals [40].
Laszló JM (2017) Hemorrhagic transformation of ischemic stroke
Vascul Dis Ther, 2017         doi: 10.15761/VDT.1000130  Volume 2(4): 6-25
The performance of the collateral supply is worse when the 
occlusion occurs in the proximal part of the vessel and the location 
of the thrombus was found to be stronger predictor of the favorable 
outcome than the collateral status itself [41]. The admission cerebral 
blood volume is also lower in case of proximal occlusion of the 
vessel. The conclusion is that proximal occlusion results in worse 
collateral supply and hence less the salvable penumbra [42]. In case of 
proximal vessel occlusion, smaller infarct core and better CS rapid 
intravascular treatment had significantly favorable impact on the 
clinical outcome [43].
A prospective cohort study involving 134 patients with proximal 
MCA occlusion reports that the longer the ischemia, the better the 
CS is. This implies that during the ischemic attack the recruitment of 
collaterals is a dynamic process. In the first hour a fast and sufficient 
collateral recruitment occur in approximately 75% of the cases to refill 
the distal part of the occluded vessel, and in the course of the next 24 
hours a slow secondary recruitment contribute maintaining the blood 
flow. The patients with sufficient collaterals had similar outcome than 
the control group without occlusion. The quarter of the patients with 
low collateral performance had significantly worse outcome [44].
As for the blood pressure, mild hypertension is associated with 
better collateral supply, although shows an inverse connection with 
3-month outcome [40].
In a retrospective study of 395 patients baseline NIHSS score, 
hemorrhagic transformation, total ischemic volume, final infarct 
size, and a modified Rankin Scale score was investigated regarding 
the grade of collateral supply and recanalisation status. The greatest 
collateral benefit occurred in patients who were recanalisation negative 
(R-). Good collateral status independently and inversely predicted 
all outcomes except hemorrhagic transformation in patients with 
recanalisation negative status and mRS >2 in patients who were 
recanalisation positive (R+). That means that in non-recanalisation 
status the collateral system had no effect on HT. It also means that a 
patient with recanalisation but without collateral supply more likely 
to suffer a HT, and with good collaterals the risk of HT is significantly 
lower. HT occurred in 174/395 (44.1%) of patients. Hemorrhagic 
infarction (HI 1/2) occurred in 133/174 (76.4%) patients overall, but 
no difference in hemorrhage type (HI versus PH) was found between 
collateral-positive and collateral-negative groups for patients who were 
R+ or R-. In multivariate analysis, collateral presence was inversely 
related to HT risk in patients who were R+, while proximal clot 
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Recanalisation and reperfusion
Ratio and timing of spontaneous recanalisation
Impact of rtPA on HT
Timing of HT after recanalisation
Ratio and timing of recanalisation with rtPA
Risk factors of HT
Clinical outcome of HI1, 
HI2, PH1, PH2
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molecular mechanisms
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Figure 5. Overview figure about the process and the influencing factors of the hemorrhagic transformation after ischemic stroke. HT, hemorrhagic transformation; HI, hemorrhagic infarct; 
PH, parenchymal hematoma; rtPA, tissue plasminogen activator; TGF-β1, transforming growth factor β1; VEGF, vascular endothelial growth factor; 15d-PGJ2, 15-Deoxy-Delta-12,14-
prostaglandin J2; PPARγ, peroxisome proliferator-activated receptor γ; SMTP, Stachybotrys microspora triprenyl phenol.
Laszló JM (2017) Hemorrhagic transformation of ischemic stroke
Vascul Dis Ther, 2017         doi: 10.15761/VDT.1000130  Volume 2(4): 7-25
location and hyperglycemia were positively related to HT in patients 
who were R+. Total ischemic volume was significantly associated 
with HT in patients who were R- but not in those who were R+. The 
frequency of poor collaterals in the R+ group was 30% whereas in the 
R- group it was only 11%, this indicates that most patients with acute 
stroke demonstrate sufficient collateral supply and in this aspect they 
are eligible for recanalisation therapy. Hyperglycemia was associated 
with a higher risk of hemorrhagic transformation in patients who were 
recanalisation-positive. HT was not related to collateral status in R- 
cases [45].
The poor pial collateral circulation was found to be associated 
with higher risk and larger size of HT. Identification of patients with 
worse collateral supply by angiography would contribute to better 
preselection of patient, who would not make profit from recanalisation 
therapy due to increased HT risk [46].
Clinical outcome of HT1, HT2, PH1, PH2 
Hemorrhagic transformation occurs in 10-40% after ischemic 
stroke, depending on the circumstances and individual influencing 
factors. Because of this high rate of occurrence a lot of studies tried 
to assess the impact of HT on short and long term clinical outcome, 
which is a cardinal question, especially because rtPA therapy hugely 
increases the risk of HT. It is difficult to compare different studies 
dealing with this topic since hemorrhagic transformation can be 
defined radiologically or clinically.
• Clinically symptomatic or asymptomatic HT: Symptomatic 
hemorrhage based on the ECASS III is defined as any intracranial 
blood which is identified as direct cause of minimum 4 National 
Institutes of Health Stroke Scale (NIHSS) points deterioration. 
HT is related to severe hypoperfusion and bigger core size. HT 
mostly occur in these areas, therefore it is important to emphasize 
that HT can stay asymptomatic regardless its volume and that 
severe early clinical condition can make it hard to identify the 
HT-related deterioration [47]. Among patients with PH 54,5% 
were symptomatic [48]. The incidence of symptomatic HT after 
thrombolysis is 6-20% [49].
• Radiological/Histological criteria: The European Cooperative 
Acute Stroke Study (ECASS):  
a. HI-1: punctuate or small petechial hemorrhage
b. HI-2: confluent petechial hemorrhage 
c. PH-1: real hematoma (<30% lesion volume) with or without 
mild space occupying effect 
d. PH-2: hematoma (>30% lesion volume) with significant space 
occupying effect and perihematomal edema [50]
Symptomatic intracranial hemorrhage is strongly associated to 
rtPA administration, which is the most feared adverse effect of the 
therapy, since symptomatic HT is independently associated with poor 
outcome [51] and was an independent predictor of in-hospital mortality 
[52]. Regarding the consequences of PH-2, the following report state 
that HT is not a reliable indicator of poor outcome, except PH-2, which 
is associated with higher early and even 90 days mortality in both 
rtPA and conservative treated patients.2 Even when rtPA is used in 
a proposed manner 2,9% of the treated patients are going to die as a 
result of hemorrhage. ECASS-I and ECASS-II trials show, that only 
PH-2 is related to worse clinical outcome, and HI-1, HI-2, PH-1 are 
rather associated with better outcome as an indicator of reperfusion 
[21]. Other studies support the observation above and report that 
patients with PH had a highly increased risk of 24-hour deterioration 
and 3-month mortality [50.54,55].
In case of conservative treatment, neither spontaneous HI nor PH 
correlated independently with poor 3 month prognosis. The explanation 
of this observation is perhaps the lack of rtPA treated patients, which 
therapy is well known associated with higher rate of PH. It is assumed 
that patients with thrombolysis-related PH may have poorer prognosis 
than patients with spontaneous PH. Just to see the distribution of 
different outcomes, out of the total number of 407 eligible patients 
12,3%, 50 patients suffered HT. HI occurred in 33 patients (66%), PH 
in 17 patients (34%), 32 patients (64%) with asymptomatic HT, and 18 
(36%) with symptomatic HT. Out of the 33 patients with HI, 6 (18.2%) 
were symptomatic and out of the 17 patients with PH, 12 (70.6%) were 
symptomatic. The timing course of the HT was the following. HT was 
observed within the first 3 days in 11 patients (22%), in day 4–7 in 20 
patients (40%), in day 8–14 in 11 patients (22.0%) and in day 15–30 in 
8 patients (16%) [56].
As for the asymptomatic HT (AHT), vast majority of the studies 
report that there is no evidence, that asymptomatic HT would worsen 
the 3-month clinical outcome [57] and even thrombolytic-therapy 
related AHT does not deteriorate short-term and long-term clinical 
outcome [58]. Although several studies remark, that in spite of the 
assumption that asymptomatic HT is not connected with early clinical 
deterioration, the 3-month outcome is maybe by factor 2 worse, than 
in case of patients without HT [59]. On the other hand, another study 
reported that asymptomatic hemorrhage was an independent negative 
factor of the outcome, but asymptomatic hemorrhage after t-PA 
thrombolysis seemed to be associated with neurological recovery, as 
a supposed sign of recanalisation and reperfusion [60]. The 90-day 
outcome in the light of HT type is the following. The best outcome was 
observed without HT, than in descending order among patients with 
HI-1, HT-2, PH-1, PH-2. These results suggest that maybe prevention of 
all types of HT go along with better prognosis, probably because of the 
edema and toxic metabolites of extravascular blood [61]. Furthermore, 
this study gives evidence that if the long term outcome is assessed, the 
risk of poor outcome in case of asymptomatic HT was 1.51-fold higher 
at 3 months and 1.44-fold higher at 1 year than for patients without HT 
and as expected this ratio in case of symptomatic HT was 2.42-fold and 
2.25-fold. Neither the symptomatic nor the asymptomatic HT affected 
the stoke reoccurrence incidence, suggesting that asymptomatic HT is 
not a risk factor for further HT [62].
Risk factors of HT
The aim of finding reliable predicting factors of HT is to identify 
the potential risk population for HT with the intention of safe rtPA 
therapeutic window extension or to exclude patients who would not 
benefit from thrombolysis.
Time to reperfusion and rtPA usage
HT incidence after rtPA administration is 10 times higher 
compared to spontaneous reperfusion [2,63]. According to the theory 
of rtPA induced HT, the reperfusion itself is the main reason and also 
the requirement of HT, beside further pathways like free radicals [64] 
or increased MMP expression [65].
Several animal and human studies clearly report: The later the 
reperfusion, the higher the HT rate. For instance, in a study on mice 
where the connection between the duration of the artificial MCA 
occlusion and the HT rate was analyzed, 0,5 h occlusion caused no HT, 
ischemia lasting 5 hours resulted in 81,8% HT rate and 54,5% mortality 
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rate and remarkably enough the permanent occlusion without 
reperfusion caused 18,2% HT incidence and 18,1% mortality rate. HT 
without recanalisation is a consequence of retrograde collateral flow. 
The observations above suggest the fact that reperfusion must have 
crucial role in the mechanism of HT but maybe not the reperfusion 
itself, but the time to reperfusion and thus the degree of BBB damage 
determines the HT rate [20,66]. 
However, a recent meta-analysis reported that reperfusion does 
not contribute significantly to HT neither with rtPA nor without rtPA, 
but in accordance with earlier studies, HT occurred twice as often with 
rtPA therapy. This observation implies that maybe further mechanisms 
beside reperfusion play more important role, than it was thought 
before [67]. Maybe the transportation of rtPA to the ischemic area and 
not the reperfusion itself results HT - since rtPA is supposed to act on 
the abluminal site of the neurovascular unit. This study also admits that 
other independent factors of HT such as ischemia severity and time to 
treatment play an important role as well. The duration of occlusion and 
the subsequent HT rate had a very strong correlation [24].
A further analysis of different aspects of HI and PH revealed, that 
HI is tend to be related to perfusion and PH is rather related to non-
reperfusion, which observation match to the fact that HI has a better 
and PH has a worse prognosis, possibly related to reperfusion status. 
That is why HI is often regarded as a good sign, as a sign of reperfusion. 
HI and PH may differ in some other aspects too [67]. Furthermore, HI 
seems to be related to the severity and duration of the ischemia, while 
PH seems to be not [68].
Age
The exact way in which age contributes to HT is not clear, most 
likely the unspecific changes in the vasculature structure and the worse 
collateral supply is responsible. Elevated release of ROS and increased 
BBB permeability was also observed. Age is definitely a risk factor of 
HT, particularly in case of rtPA treatment, although altogether even 
elderly over 80 benefit from rtPA treatment [69]. 
Stroke severity/NIHSS (National Institutes of Health Stroke 
Scale)
According to the ECASS III classification of HT, symptomatic HT 
is defined by an increase of at least 4 points in the NIHSS [70]. Stroke 
severity, that correlates with the infarct size is independent and one 
of the most reliable predictive factor for HT [70]. Higher NIHSS on 
admission is associated with increased risk for symptomatic HT [71]. 
Systolic blood pressure
Acute high blood pressure is proved to contribute to HT by 
increasing the BBB permeability. Reducing blood pressure below 
185/110mmHg before rtPA administration is part of the guidelines 
[72,73]. 
Hypertension history
Chronic hypertension alters vasculature structure also in the brain. 
This remodeling process involve increased vascular resistance, reduced 
vascular compliance and impaired collateral circulation and further 
contributes to BBB disruption with the tendency of increased ROS and 
MMP generation [2]. Apparently there is an interesting connection 
between age and hypertension. In chronic hypertensive rats there 
was no difference of HT rate between young and old animals, though 
among normotensive rats a higher incidence of HT occurred in the 
older group of rats, implying that in normotensive cases age might has 
higher influence on HT [21]. 
Hyperglycemic or spontaneously hypertensive rat models make 
out good candidates to investigate the background mechanisms of 
HT, new neuroprotective and BBB protective agents, because of their 
tendencies to higher rate. 
Glucose
Acute high glucose level is strikingly associated with higher rate of 
BBB disruption, HT and worse outcome in all animal models and in 
human retrospective studies as well. 30-60% of all patients with stroke 
have elevated admission serum glucose level, as a result of increased 
sympathetic activity after stroke. A smaller part of the patients has 
manifest diabetes mellitus. Advantages and disadvantages of serum 
glucose level correction in acut stroke patients is under debate, since 
overcorrection related hyperglycemia can be fatal. 
Effect of increased glucose level at the time of stroke has two 
sides. During the ischemia, higher level of serum glucose has the 
potential to maintain the ATP level in the neurons even in the lack of 
oxygen via anaerobic glycolysis which is inevitably followed by lactate 
acidosis, causing altogether longer cell survival interval, giving time 
for intervention. Lactic acidosis under a certain level has an assumed 
neuroprotective effect due to inhibiting NADPH oxidase, but after a 
while severe low pH causes protein denaturation itself, although there 
is no evidence that the negative effect of hyperglycemia is preventable 
by normalizing the pH. In contrast, during the reperfusion high 
glucose level has definitive destroying effect on the BBB, because in case 
of reperfusion the by hypoxia and acidosis blocked NADPH oxidase is 
released from inhibition, and its superoxide production is going to be 
enhanced by hyperglycemia. 
The neurons are able to metabolize exclusively glucose, but not 
fatty acids. In details, glucose is the exclusive substrate in production 
of NADPH, which has central and biphasic role regarding the ROS 
formation and elimination. NADPH is part of the pathway producing 
glutathione, which is strongly antioxidant. In addition, NAHPH is 
used by nitric oxide synthase to generate NO and by NADPH oxidase 
to produce superoxide. Oxygen free radicals in ischemia-reperfusion 
are generated in mitochondrial electron transport chain as well. This 
process is absolutely glucose-dependent since all reducing equivalents 
passing through the mitochondrial electron transport chain originate 
from glucose. 
Other mechanisms of glucose exacerbated stoke are supposed 
to involve enhanced glucose-sodium transporter activity, increased 
abnormal protein glycosylation and intensified post ischemic 
inflammatory response. As expected in the core region, where no 
blood flow can be detected, the serum glucose level had no influence. 
Supported by the results of several experimental studies, the high serum 
glucose indeed did not exacerbate the core injury and might rather 
have beneficial effect. In the area of the penumbra, between the core 
and the non-ischemic tissue, where decreased but present blood flow 
is detectable; the higher glucose can have its above discussed negative 
effect. 
The excess of glucose over oxygen forces neurons to continue 
glucose metabolism in an anaerobic way causing lactate acidosis. This 
pathway produces just 1/16 part of the ATP/glucose molecules that the 
aerobic pathway would be able to generate. Penumbra is a dynamic and 
unstable area, where a relatively high blood-flow can wash the lactate 
out. Due to this heterogeneous effect it is hard to predict the effect of 
hyperglycemia in ischemic brain tissue, nevertheless in most cases the 
negative effect surely dominates. In the reperfusion phase via ROS 
production, hyperglycemia has undeniably negative impact [74].
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Further studies give evidence to the theory above. Among patients 
with proved diffusion/perfusion mismatch, admission hyperglycemia 
was strongly associated with infarct size, progression of penumbra 
into definitive infarct, and lactate peaks in the area of penumbra. In 
comparison, among patients showing no diffusion-perfusion mismatch 
admission hyperglycemia was not associated to the parameters 
mentioned above [75]. As expected, in case of lacunar infarcts, where 
end arterial vascular areas are occluded and the collateral supply is 
weak, hyperglycemia had no notable negative but had rather positive 
effect [76]. 
Evidences show that high glucose level has direct effect on 
endothelial cells causing increased edema formation, hemorrhage 
transformation and reduced microvascular reflow. The underlying 
mechanisms include increased endothelial protein kinase C activation, 
amplified inflammatory responses and elevated superoxide generation 
[77-79].
Hyperglycemia also contributes to rtPA induced HT and poor 
outcome, even in the combination of mild hyperglycemia and low dose 
rtPA [80,81]. This effect could be suspended in rat models with the 
NADPH oxidase inhibitor apocynin in ischemia-reperfusion models 
suggesting that hyperglycemia enhanced HT is mediated by NADPH 
produced superoxide [82]. 
Based on the observation that hyperglycemia increased the 
HMGB-1 level in brain tissue early after stroke onset and that all of the 
negative effects of hyperglycemia mentioned above were suspended by 
the administration of a specific HMGB-1 inhibitor, glycyrrhizin it is 
suspected that extracellular HMGB-1 contributes to the hyperglycemia 
deteriorated clinical outcome and neurological deficit, larger infarct 
volume, edema and BBB disruption [83].
Several human studies proved as well that hyperglycemia have 
unfavorable effect on infarct growth and poor outcome with or without 
thrombolysis [84,85]. An ongoing trial at the time of this review called 
the Stroke Hyperglycemia Insulin Network Effort (SHINE), tries to 
provide novel information about the risks and benefits of hyperglycemia 
management in acute stroke patients [86]. 
Diabetes
History of high glucose level also contributes to higher HT incidence 
in several supposed ways [87]. Most likely the ROS induction [88], a 
modified leukocyte function [89], impaired BBB permeability [90], 
microvascular remodeling, altered vessel structure and angiogenesis 
via VEGF and peroxinitrit signaling [91], involving membrane-type 
matrix metalloprotease (MT-MMP) and c-src kinase activation [92] 
and further inflammatory cascades contribute to the HT [93]. A further 
study reports that after streptozotocin induced hyperglycemia and 
transient MCA occlusion the infarct volume and area was not altered 
by hyperglycemia, but the HT volume was significantly higher. The 
main cause was found to be the endothelial dysfunction, in particular, 
a mitochondrial dysfunction, which was provoked by MMP-9 in a ROS 
independent manner, causing caspase-3 activation. This key movement 
starts the apoptotic cascade. The process continues in fragmentation 
and vacuolation of the mitochondria with subsequently decreased ATP 
level and decreased mitochondrial membrane potential followed by 
decreased cell proliferation, worse regeneration capacity, severer BBB 
disruption, and aggravated HT volume [87]. 
HbA1c was found to be an important predictor of symptomatic HT 
after ischemic stroke [94].
Body weight
Increased body weight was found to be an independent predictor of 
symptomatic HT. Especially patients above 95 kg are at high risk [80].
Congestive heart failure
Congestive heart failure as a source of cardiac embolic stroke was 
observed to be associated with higher incidence of symptomatic HT 
and PH. The assumed background mechanism is the distal migration 
of embolic fragments that allow reperfusion of ischemic-weakened 
vessels [95].
Atrial fibrillation
Presence of atrial fibrillation in stroke patients most likely via poorer 
collateral blood supply is associated with more severe hypoperfusion 
and hence with increased infarct growth and volume, more frequent 
and more severe HT and worse stroke outcome [96].
Renal impairment, estimated GFR
Reduced eGFR did not increase the risk of symptomatic HT, but 
was associated with significantly increased HT rate, especially in strokes 
with large artery atherosclerosis but not in strokes with cardioembolic 
etiology [97].
Antiplatelet usage
An altered hemostasis contributes to HT when BBB disruption 
already occurred, and may make HI to evolve into PH. Antiplatelet 
or dual antiplatelet usage before rtPA treatment or antiplatelet use 
within the first 24 hours of rtPA treatment increases the risk of rtPA-
related HT [95,98]. Dual therapy of aspirin and clopidogrel has strong 
association with the risk of symptomatic HT after rtPA treatment. 
Aspirin intake as monotherapy is an independent predictor of HT as 
well, however not as strong as the dual platelet inhibition [80].
Platelet count
Platelet count under 100.000/ µl is a contraindication for rtPA 
administration [99].
Anticoagulant/international normalized ratio/partial 
thromboplastin time
INR>1,7 is a contraindication for rtPA [99]. After cardioembolic 
stoke, secondary prophylaxis with administered heparin or enoxaparin 
hugely increases the risk of HT, though warfarin prophylaxis seems to 
be safe even if started shortly after stoke [100], though this question is 
quite complex and still under debate.
Blood markers
NSE: Neuron specific enolase has a 48 hour half life in serum and 
can be found in neurons and in the neuroendocrine system [101]. It is 
reported, based on serial NSE serum level measurements of 83 patients 
after stroke onset that the NSE level changing pattern significantly 
depends on the stroke mechanism. Specifically, a second peak of 
NSE level was associated with cardioembolism and hemorrhagic 
transformation. The first peak of NSE level is normally reached within 
the first 96 hours after onset, but the exact timing strongly depends 
on the size of the penumbra causing a continuous cell death and a 
continuous elevating or at least maintained NSA level [102]. NSE was 
found to be a significant predictor of lesion volume, early and 30-day 
functional outcome [103].
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S-100 Protein: Measurement of serum S-100 protein levels in 
the first 10 days after stroke onset helps to predict long term clinical 
outcome and final infarct size [102]. The level of S-100 protein 
independently predicts HT before rtPA treatment, however with too 
low diagnostic accuracy to be useful in the preselection of patients for 
rtPA therapy [104,105]. 
MMP-9 level: Analysis of peripheral blood samples taken from 
stroke patients revealed an increased level of MMP-9 level. The 
elevation correlated with worse clinical outcome, bigger infarct size and 
higher rate of HT. MMP-9 level predicted the HT with the sensitivity 
of 87%, a specificity of 90%, a positive predictive value (PPV) of 61% 
and a negative predictive value (NPV) of 97%. The source of the MMP-
9 elevation in early stroke is the over-expression of MMP-9 gene in 
neutrophil granulocytes. MMP-9 and neutrophil levels are elevated in 
the cerebrospinal fluid as well. Since rtPA itself promotes neutrophil 
degranulation, a peak of MMP-9 elevation can be detected 30 minutes 
after rtPA administration as well [105-107]. 
Fibronectin level: High plasma fibronectin level after ischemic 
stroke is significantly and independently associated with subsequent 
HT in case of rtPA administration, as a possible marker of the extension 
of BBB disruption. The elevated fibronectin in the serum arise at least 
from two sources. First the disruption of the BBB and second, as a 
natural response to injury, an increased fibronectin production leads 
to serum fibronectin elevation. Experimental animal studies have 
reported that endothelial cell injury induces fibronectin production 
to promote re-endothelialization. Furthermore, administration of 
synthetic fibronectin peptide V within 3 hours after reperfusion 
reduces the final infarct volume [107].
Tight junction proteins: Circulating principal TJ proteins like 
occludin (OCLN), claudin 5 (CLDN5), zona occludens 1 (ZO-1) are 
biomarkers of BBB damage and evaluation their serum levels in case 
of early stoke may help to screen patients who are at high risk for HT 
caused clinical deterioration, since they correlating with the extension 
of BBB breakdown and HT occurrence. The degradation and increased 
appearance of these proteins in the serum is mainly mediated by MMP-
9 overexpression [105]. 
Fibrinogen level: The analysis of blood samples taken from stroke 
patients 2 hours after rtPA administration show a strong correlation 
between the fibrin degradation protein level and the PH occurrence 
rate. A supposed coagulopathy caused directly by the thrombolytic 
process involves excess fibrinogenolysis early after thrombolysis with 
the release of fibrin degradation products (FDP), acting as antithrombin 
and inhibiting fibrin polymerization. The risk of PH above 200mg/L 
of FDA level become significant, although already above 100mg/L the 
potential risk for PH is increasing. Hence patients with FDP > 100 mg/L 
at 2 hours after rtPA administration based on their prehemorrhagic 
antithrombotic state, new antithrombotic drugs should be avoided for 
72 hours. FDP level is most likely dependent on the thrombolytic agent. 
FDP level was significantly higher in patients treated by streptokinase 
than in patients treated by rtPA, might contributing to the higher level 
of symptomatic HT rate in case of streptokinase administration [48]. 
Ferritin level: Elevated serum ferritin level in the first 24 hours 
after stroke onset is independently associated with HT and PH as 
well. In case of PH the risk is 4.9 times higher compared to patients 
with normal admission ferritin levels. Furthermore, ferritin level 
above 171.8 ng/ml was independently connected to symptomatic HT 
with a 5.7 times higher odds [108]. Also, earlier studies reported, that 
higher ferritin level is related to poor outcome and large lesion size 
in patients treated with rtPA. The supposed underlying mechanism of 
this neurotoxic effect caused by increased body iron storage involves 
production of hydroxyl radicals and endothelial injury [109]. The 
hypoxia induced superoxide radicals have the ability to release free, 
toxic iron from ferritin. Free iron generates further free radicals, 
initiates and propagates lipid peroxidation contributing to BBB 
breakdown. The deleterious effect on this pathways are assumed to be 
dependent on the concentration of tissue iron, hence serum ferritin as 
indicator of body iron saturation can predict HT rate [110]. 
Activated protein C: APC is a plasma serine protease with a 
well known anticoagulant effect and a recently recognized anti-
inflammatory, anti-apoptotic, neuro- and vasculoprotective effect. 
These phenomenons are presumed to be based on endothelial cell 
protein C receptor (EPCR) and protease-activated receptor 1 activation 
leading to gene expression modulation in endothelial cells. These 
beneficial effects made APC eligible for further studies with the hope to 
extend rtPA window. Unfortunately, only in vitro and rodent models 
showed favorable results. In humans, an increased level of APC after 2 
hours of rtPA treatment was strongly associated to HT. The elevation 
of the APC level after thrombolytic therapy was well known but now 
its negative influence on HT is clarified. Apparently, in humans the 
anticoagulant effect overwhelms the neuro- and vasculoprotective 
effect. The impact on the coagulation system involves irreversible 
inactivation of Va and VIIIa factors breaking the amplification of the 
coagulation process. In addition, it inactivates plasminogen activator 
inhibitor 1 (PAI-1) and weakens the activation of thrombin-activatable 
fibrinolysis inhibitor (TAFI), promoting fibrinolysis [111-113]. 
Thrombin activatable fibrinolysis inhibitor (TAFI): High 
baseline of TAFI level on admission were associated with higher rate 
of symptomatic HT [114] and was reported to be associated with better 
reaction on rtPA treatment with higher recanalisation rate, although 
TAFI inhibits fibrinolysis. The background of this apparent paradox 
is might be the TAFI consumption theory, which says that lower level 
of TAFI indicates higher affinity to fibrin and therefore high TAFI 
activity and elevated TAFI indicate low activity leading to fibrinolytic 
tendencies [115].
Plasminogen activator inhibitor-1 (PAI-1): Low baseline PAI-1 
levels on admission are correlating with symptomatic HT after rtPA 
treatment. The underlying mechanism includes the altered fibrinolytic 
system and a tendency for bleeding disturbances [114]. High level of 
PAI-1 was found to be associated with worse answer to rtPA therapy 
with higher rate of recanalisation resistance [116]. 
Vascular adhesion protein-1 (VAP-1): The inflammatory response 
after stroke is mainly promoted and maintained by polymorphonuclear 
cell extravasation into the infarcted area. In this process participates 
the VAP-1 protein which is an important protein on the surface 
of endothelial cells – and circulating protein as well - involved in 
recruitment of lymphocytes and neutrophils via its semicarbazide-
sensitive amine oxidase (SSAO) activity. Polymorphonuclear cells 
are indeed presented in big density around VAP-1 positive vessels in 
the infarcted area, therefore further studies are planned to examine a 
VAP-1/SSAO inhibitor with the purpose of extending the rtPA time 
window. There was no difference found regarding the serum VAP-1/
SSAO activity between stroke patients without HT and control group, 
but elevated baseline VAP-1 level/SSAO activity measured before rtPA 
treatment strongly predicted PH and worse neurological outcome, 
making VAP-1 a possible candidate to efficiently preselect stroke 
patients eligible for rtPA therapy [117]. 
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PDGF-CC isoforms: PDGF signaling pathway consists four 
ligands, PDGF A,B,C,D and two receptors, PDGFR alpha and beta. 
The ligands form functional homodimers, except for A and B that can 
form functional heterodimers as well. rtPA activates CC homodimers 
allowing CC dimers to trigger PDGFR alpha leading to increased BBB 
permeability, furthermore the blockage of PDGFR alpha with imatinib, 
which is tyrosine kinase inhibitor, can weaken the hemorrhagic 
complications caused by rtPA administration. All these reports point 
out that PDGF pathway has a central role maintaining BBB integrity. 
Serum PDGF-CC levels on admission and after 24 hours of rtPA 
treatment are associated with HT [33]. 
15d-PGJ2: Elevated plasma 15d-PGJ2 concentration is associated 
with good early and late neurologic outcome and with smaller 
infarct volume. 15d-PGJ2 is a non-enzymatic modified variant of 
PGD2. 15d-PGJ2 is an endogen ligand of PPARγ which is a nuclear 
hormone receptor playing an extended regulating role in several 
cellular signaling mechanisms, such as apoptosis, oxidative stress and 
neuroinflammation [118]. 
Uric acid: As an endogenous antioxidant: High uric acid level 
was significantly associated with lower rate of HT and with better 
clinical outcome among patients treated with rtPA. Uric acid, based 
on its antioxidant effect neutralizes ROS burden and all the complex 
mechanisms connected to reactive oxygen species in case of an ischemic 
stroke [119].
Calcium
Low serum calcium level at admission was significantly and 
independently associated with HT after rtPA treatment. Two underlying 
mechanism is assumed. First, calcium is an essential cofactor in the 
coagulation cascade; hence lower serum calcium level may promote 
coagulation disturbances causing bleeding complications. Second, 
decreased serum calcium level may induce vasoconstriction in the peri-
ischemic zone leading to locally elevated blood pressure and HT [120].
Genetics
Leukocyte mRNA (Amphiregulin, MARCH7, SMAD4, IRAK3, 
INPP5D, MCFD2, VEGI) (see also X/4)
alfa-2-macroglobulin (A2M): Single nucleotide polymorphism 
rs669 (Val1000Ile) in A2M was associated with HT. It may induce 
decreased activated/inactivated A2M ratio and decreased A2M activity. 
A2M is a general protease inhibitor. After activation it sterically 
binds proteases such as rtPA, plasmin or MMP-9. Then, the complex 
binds to lipoprotein-related protein, followed by internalization 
and degradation. A2M was reported to play role in migration and 
degranulation of neutrophils as well. Elevated level of A2M in the CSF 
is a reliable sign of BBB disruption [121]. 
Factor XII: rs1801020 (4C>T) mutation of Factor XII predicted 
in-hospital death after rtPA administration due to increased factor 
XII activity. The observed phenomenon is assumed to be based on 
interference in the fibrinolytic and kinin-kallikrein pathways [121].
Factor XIII: Carriers of FXIII V34L polymorphism have 2.5-fold 
risk to die after rtPA treatment than patients with V/V genotype, since 
these patients show significantly higher HT rate. This polymorphism 
may affect the formation and structure of the fibrin clot [122].
Collagen IV: Mutations in the COL4A1 gene, which encodes 
procollagen type IV alpha 1 is promoting small vessel disease and 
intracerebral hemorrhage by altering the structure of the basal lamina. 
These mutations may influence the process of HT in ischemic stroke as 
well [123,124]. 
MMP-9: -1562C/T polymorphism in the matrix metalloproteinase-9 
gene was found to be related to HT. T allele was a protecting factor of 
HT in the investigated population [125]. 
Survivin gene: 241C/T polymorphism in the promoter of the 
survivin gene is associated with lower risk of HT. Stroke patients 
presenting this mutation show less severe HT if the HT occur and have 
lower risk for PH. Survivin is an anti-apoptotic molecule inhibiting 
caspase-3 [126]. 
Neuroimaging
Infarct size/diffusion weighted imaging infarct volume: 
Increased lesion on DWI and increased delay on PWI is associated 
with higher rate of HT. Severe delay on PWI was proven to be more 
important factor for HT formation than tissue status on DWI [49,127].
Low cerebral blood flow or volume: Baseline very low cerebral 
blood volume on MRI imaging is a powerful predictor of PH after 
thrombolysis; furthermore it appears to be more powerful than DWI 
or PWI [128]. 
Early infarct sign: Alberta stroke program early CT score 
(ASPECTS) is a topographic CT scan score. The lower the ASPECTS 
score the bigger the infarcted area, thus bigger the risk of HT. ASPECT 
score is an independent predictor of HT with the sensitivity of 85,5% 
and with the specificity of 75% [69,129,130]. 
Dense cerebral artery sign: Hyperdense cerebral artery sign is 
independently predictive for HT after thrombolytic therapy [130,131].
Leukoaraiosis: White matter hyperintensities. Describes the 
nonspecific changes in the cerebral white matter frequently seen on 
CT and MRI in aged individuals and even young adults sometimes. 
Many patients can have leukoaraiosis without any associated clinical 
abnormality. However, underlying vascular mechanisms are suspected 
to be the cause of the imaging findings. Hypertension, smoking, 
diabetes, hyperhomocysteinemia, and heart disease are all risk factors 
for leukoaraiosis. Leukoaraiosis was proved to be a risk factor for 
symptomatic HT after rtPA administration [69,132].
MRI enhancement pattern: Early gadolinium enhancement on T1 
weighted MR images of acute stroke patients are good predictors for 
subsequent symptomatic HT [133]. 
BBB permeability: Admission CT perfusion derived permeability-
surface product maps show promising results in distinguishing patients 
who are likely to develop HT after ischemic stroke [134]. 
Hyperintense Acute Reperfusion Marker (HARM): HARM is the 
gadolinium enhancement of the cerebrospinal fluid and is regarded 
as a reliable sign of BBB disruption. Thrombolytic therapy is an 
independent factor of HARM, and HARM is an independent predictor 
of HT [135].
Apparent diffusion coefficient value: The percentage of low ADC 
values in ischemic areas destined to HT are greatly higher than in other 
lesion areas [125]. 
Collateral flow: After occlusion of a main artery, leptomeningeal 
backfilling can determine the size of the penumbra and the final lesion 
size as well. Poor collaterals are associated with larger infarct size 
and worse functional outcome at 3 months and this promotes higher 
HT rate, but just in case when recanalisation occurs, suggesting that 
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reperfusion has a major role in HT. Assessment of baseline collateral 
supply can contribute to the decision leading to thrombolytic therapy 
[136].
Rating scores
Rating scores are suitable to identify patients who are at high 
risk for cerebral parenchymal hemorrhages, but alone none of them 
were sensitive enough to exclude otherwise eligible patient from 
rtPA treatment. According to a prospectively collected data of 3012 
eligible patients, the SPAN-100 has the worse, and SEDAN has the 
best predictive power, though none of the scores reached better than 
moderate performance. 
•	 HAT - Hemorrhage After Thrombolysis (NIHSS, glucose, early 
infarct sign, diabetes) 
•	 MSS - Multicenter Stroke Survey (age, NIHSS, glucose, platelet 
count) 
•	 SITS-SICH - Safe Implementation of Thrombolysis in Stroke (age, 
NIHSS, glucose, systolic BP, hypertension history, body weight, 
time to thrombolysis, antiplatelet)
•	 SEDAN score (blood sugar, early infract sign, dense artery sign, age, 
NIHSS) 
•	 GRASPS score (glucose, race, age, systolic BP, NIHSS, sex) 
•	 SPAN-100 index (age, NIHSS) 
•	 iScore (age, NIHSS, glucose, sex, stroke subtype, atrial fibrillation, 
congestive heart failure, prior myocardial infarction, smoker, 
cancer, dialysis, prior disability) [137].
Pathophysiology and molecular mechanisms
To provide a detailed picture about the structural changes during 
the BBB breakdown investigators used 3 different rat groups with 
different occlusion duration including rats with transient MCAO lasting 
90 minutes, rats with permanent MCAO and embolic MCAO. Result 
analysis proceeded in multiple levels. Endothelium was visualized by 
fluorescence microscopy with the help of isoleticin B4, furthermore, 
FITC albumin was administered after 24 hours from ischemia onset. 
After that, in the histological process peroxidase conjugated anti FITC 
IgG was applicated with subsequent staining by diaminobenzidine 
to make the leaked FITC albumin visible for light and electron 
microscopy demonstrating the presence of the BBB leaking. Anti 
occludin, claudin-3, claudin-5 were used to make the TJs visible. Anti 
microtubule associated protein (MAP2) and anti heat shock protein 70 
(HSP70) detection was used to define the molecular penumbra. 
The results are the followings: Isolectin IB4 Antibody Staining 
showed endothelium alternations in areas of extravasation. This 
endothelium lost via apoptosis was found to be the main source of 
the BBB disruption. The endothelium loss had four good separable 
ultarstructural phases. 
• First stage: Endothelial cell swelling, intracellular edema, no FITC-
albumin extravasation.
• Second stage: Endothelial membrane fails to maintain the barrier 
function, the  apical membrane becomes leaky, causing 
intracellular FITC-albumin-DAB grains, less cell edema and the 
basal membrane is intact. 
• Third stage: Endothelial structure is completely lost, FITC albumin-
DAB in the neuropil, beyond the basal membrane which is intact.
• Fourth stage: The basal membrane is degradated via MMP 
upregulation, causing erythrocyte extravasation, ending up in HT
In areas where FITC albumin extravasation was observed vessels 
showed stage 3 and stage 4 degeneration. Though, outer from the 
border zone of the tracer extravasation no stage 4 was observed but 
the vessels mostly presented stage 1 degeneration which corresponds 
to endothelium swelling. This swelling is partly the consequence of 
ischemia activated connexin-43 hemichannels activation. The results 
imply that stage 1 represents the initial phase of the BBB breakdown 
and that stage 3 or 4 is requirement of the extravasation. The tracer 
extravasation exceeded the by HSP70 and MAP2 defined molecular 
penumbra. The border zones of the tracer extravasation correspond to 
the outer layers of the penumbra. FITC extravasation border zone did 
not match with the molecular penumbra. 
TJ proteins were unaltered in all groups. Occludin, ZO 1 and 
claudin ratio of the affected area did not differ from the contralateral 
hemisphere. The staining pattern was intact, however their special 
function is supposed to be altered [138]. Several studies proved that 
ischemic circumstances are causing TJ protein degradation followed 
by BBB breakdown. Surprisingly there were no difference in the grade 
of endothelium degeneration and FITC leaking in the transient and 
in the permanent group, which implies that loss of endothelial barrier 
is not a reperfusion injury [139,140]. This observation may serve as a 
base to the recent meta-analysis which found no connection between 
reperfusion and HT rate [67]. 
Due to resolution limits of imaging techniques, it is not surprising 
that autopsy reports show 71% HI rate among ischemic stroke cases. 
As for the mechanism of PH, it is likely that the primary bleeding of 
smaller vessels and the subsequent neuroinflammatory response is 
responsible for the secondary disruption of surrounding vessels [21]. 
Pathophysiology of ischaemic stroke and the subsequent HT involves 
various pathways that will be discussed in the further paragraphs.
The dynamic of BBB disruption in case of ischemic 
stroke. 
The blood brain barrier comprises endothelial cells, pericytes, 
astrocytes and basal lamina. The basal lamina is basically built from 
collagen IV, laminin and fibronectin. The tight junctions between the cells 
are constituted of occludin, claudin-3, claudin-5, ZO-1, ZO-2 and ZO-3.
The time course of the BBB disruption can be assessed by contrast 
MRI. In the BBB disruption 2 peaks can be observed, the first take place 
within the first 2-6 hours after stroke onset, and is enhanced between 
4-8 hours and between 12-16 hours after onset, which suggests that the 
infarct is rather a plastic and the reperfusion is a dynamic process, with 
hyperemic and hypoperfusion phases. The second peak is a delayed 
BBB disruption which occurs after 18-24 hours after onset and lasts 
for up to several weeks. The molecular mechanisms of the early and 
delayed disruption differ in several aspects. The early BBB breakdown 
is mediated by ROS, blood MMP-9 and MMP-3, and the delayed 
disruption after 18-24 hours is promoted by brain MMP-9, brain 
MMP-3 and several other brain proteins, vascular remodeling and 
neuroinflammation. Although the molecular pathways are different, 
they are not sharply separated; there are several overlaps and positive 
feedbacks. The point is that early HT does not predict the delayed HT 
and that the therapeutic targets supposed to be different [2].
Early disruption of BBB and early HT 
ROS, like superoxide and peroxinitrit, arise mainly after 
reperfusion from different sources; from ischemic damaged cells or 
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from inflammatory cells, as crucial part of the neuroinflammatory 
process. The ROS forming mechanisms include changes in intracellular 
mitochondria and in the NADPH oxidase pathway, MMP mediated 
proteolysis and the positive feedback of inflammatory mediators. 
Reperfusion causes a ROS burst with a subsequent greatly elevated 
level of ROS, compared to non-reperfusion mice, where a low initial 
level of ROS was followed by a slow increase in the first 3 hour. The 
early reperfusion mediated ROS burst can be effectively prevented by 
administration of ROS inhibitors in animal models, but unfortunately 
not in humans. 
In addition, mice with SOD1 (superoxide dismutase 1) defect or 
NOX2 (nicotinamide adenine dinucleotide phosphate oxidase) show 
a dramatically reduced rate of BBB disruption as a consequence of 
milder ROS burden. Blood markers of ROS burden like F2 isoprostane 
or 3-nitrotyrosise are elevated after 6 respectively 3 hours after stroke 
onset. Both of them are end products of non enzymatic oxidation by 
ROS. The associated factors enhancing ROS injury are the followings: 
age, glucose level, diabetes mellitus, infarct size, congestive heart 
failure, renal impairment [2]. 
MMP-2, MMP-3, MMP-9 in early HT 
The natural reaction after an ischemic injury is the powerful 
activation of the immune system. After 30 minutes of ischemia occurs 
the first step, namely the leukocyte adhesion to the vascular endothelial 
cells of the affected area and by 6 hours the leukocyte infiltration. Both 
process increase capillary permeability. The plasma activity of MMP-9 
in mice within 3-8 hours is increased. After stroke, the MMP descend 
from two sources, from the brain cells and from immune cells. In 
leukocyte depleted mice the early disruption did not occur, whereas in 
mice with brain MMP-9 deficit early disruption occurred, but not the 
delayed disruption. Conclusion is that the early sources of the MMP-9 
are the leukocytes. MMP-9 inhibitors decrease the HT incidence. In 
humans, serum MMP-9 level rising early, and reaches its peak by 6-8 
hours, and returns its basic level by 24 hours. Although a couple of 
studies have found increased level of MMP-9 after 24 hours, whose 
reason is unclear, but maybe the size of the lesion, co-morbid diseases 
or a biphasic elevation is responsible, in addition MMP-9 mRNA in 
leukocytes are also elevated by 3-5 hours and return to baseline by 
24 hours. Depleting leukocytes with vinblastin or anti neutrophil 
antibody can decrease BBB breakdown and neutrophil activation with 
lipopolysaccharide can increase disruption. MMP-9 acts on the tight 
junctions and on the basal lamina. MMP-9 from the blood destroy 
directly the tight junctions or can be taken up by endothelial cells itself 
and then acting on the basal lamina. Another way is that infiltrating 
neutrophils emit MMP that reaches TJs and basal lamina. The level of 
TJ degradation products in blood is predictive for HT. 
Brain MMP-2 level is increasing in 1-3 hours after onset and 
additionally remains elevated for days. This observation has a supposed 
role in early disruption, but its main effect contributes to the delayed 
HT. Possibly sources of MMP-2 are astrocytes, endothelial cells and 
leukocytes. Activators of MMP-2 expression are furin, thrombin, 
xanthine oxidase, MTI-MMP. All of them show an elevated serum 
level after stroke. MMP-2 knockout mice presented reduced HT rate, 
smaller hemorrhagic volume and better neurological function. MMP-2 
seems to ha a role in both early and delayed form of HT. 
Brain caveolin 1 membrane protein level is decreased during the 
ischemic attack, and according to a study on cav 1 knockout mice 
maybe caveolin in the brain tissue is associated with ROS and MMP-
2 inhibition and contributes to the BBB integrity by influencing the 
claudin-5 TJ protein [2].
Serum leukocytes in early HT
After analyzing the mRNA expression pattern in blood leukocytes 
3 hours after ischemic stroke but before rtPA administration, 6 genes 
seem to be predictive to HT, though 29 different genes showed altered 
expression in patients who suffered HT. 
Membrane associated ring CH 7
(MARCH7 or axotrophin) MARCH7 is an ubiquitin ligase which 
regulates membrane receptor expression is leukocytes and in other 
tissues as well. The increased serum level observed in stroke patients 
with HT may connected to downregulation of leukocyte surface 
proteins like MHC I and II, CD86 or ICAM1 and can shift T-cell 
response toward a Th17 pro-inflammatory response. 
VEGF inhibitor 
Expression was decreased in patients presenting HT. It may 
contribute to HT by altering the apoptosis of inflammatory cells via 
Caspase 8/ Fas ligand or decreasing the regeneration potential of 
damaged endothelium.
Amphiregulin 
Expression was elevated. Amphiregulin is a ligand of EGFR 
and enhances neutrophil migration by altering E-Catherin in tight 
junctions, activating the MAP kinase pathway and promote MMP-9 
and VEGF release inducing HT.
SMAD 4
Expression was also elevated, which is the target of TGF-ß and 
its function includes the regulation of the N-Catherin expression in 
endothelial cells, so stabilizing the BBB. No wonder that a hereditary 
lack of SMAD4 is related to hemorrhagic teleangiectasia and extra 
cellular matrix anomalies such as aneurysms and aortic dissection.
Two target genes of SMAD4 were also elevated, interleukin-1 
receptor associated kinase 3 (IRAK3) which participate in TOLL-like 
receptor signaling and Inozitol phosphate-5-phoshpatase (INP5P), 
which regulates the proliferation of myeloid cells. TGF beta pathway of 
leukocytes including SMAD4 and IRAK3/INP5P most likely plays an 
important role in the process HT [141]. Although TGF beta/SMAD2 
pathway in a subset of monocytes, that as part of the neuroinflammation 
migrates into the brain in the 1-7 days after stroke onset seems to 
enhance BBB integrity and is associated with a lower rate of HT [142]. 
Multiple coagulation factor deficiency 2 
Gene expression was decreased. This gene manages the transport 
of factor V and VIII from endoplasmatic reticulum to Golgi apparatus, 
thus the lack of it results in bleeding disorder [141]. 
Delayed HT
The molecular mechanism of BBB disruption after 18-24 hours 
from stroke onset differs from the early form; it is delayed, prolonged 
and more profound. Brain MMP-9,2,3,10,13,14 and other protease like 
plasmin, endogenous rtPA, urokinase, cathepsin, TNF alpha converting 
enzyme have a role in this process. In neutrophil depleted mice the 
MMP level in the brain remains unchanged after 24 hours from onset, 
suggesting that the source of the responsible MMPs is the brain itself. 
Brain MMP-9 is released in the first line from endothelial cells than 
from neurons, microglia, and astrocytes. The signaling pathways that 
promote MMP-9 release are the following ones: ROS, TLR4, NFkB, 
HMBG1 receptor, TNF alpha and IL-1. MMP-9 activation is mediated 
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by MMP3, which turn proMMP-9 into activated MMP-9. MMP-3 is 
released from pericytes and endothelial cells within 24 hours after onset 
and especially in case of rtPA administration plays a central role. MMP-
3 knockout mice show decreased rate of HT, and after administration 
of broad spectrum MMP inhibitor, the HT rate did not get better, 
suggesting how important the MMP-3 regulation pathway is. MMP-
3 is promoted via inflammation or rtPA activated LRP (lipoprotein 
receptor protein) and NFkB pathway. MMP degrade the TJs, causing 
the appearance of its end product proteins in blood, such as claudin 5, 
occlusion, ZO-1, and destroy basal lamina as well [2].
Hyperglycemia induces MMP-3 activation and is associated with 
HT and worse outcome. MMP-3 inactivation in hyperglycemic rat 
models significantly reduced HT rate and improved the outcome [143]. 
TIPM-1 or TIMP-2 (tissue inhibitors of metalloproteinases) 
knockout studies on mice support the hypothesis that TIMP-1 and 
TIPM-2 inhibits MMP-9 activity and play a neuroprotective role in 
case of cerebral ischemia. In TIMP-1 knockout mice, BBB breakdown 
and leakage, neuronal apoptosis, and ischemic damage after ischemia 
was significantly higher. Mice without TIMP-2 gene showed increased 
BBB leakage and apoptosis without any change in the ischemic damage. 
TIMP-1 could be a potential target of neuroprotective therapy [144]. 
Also, the increase of the MMP9/TIMP1 ratio is significantly associated 
with symptomatic HT [145]. 
Neuroinflammation 
Inflammation after an ischemic event is a natural reaction of the 
body, simultaneously causing secondary brain damage and playing 
basic role in healing-repair mechanism, balancing between the early 
destructive inflammation and the regenerative environment. 
Monocyte infiltration peaks in several days after onset, contributing 
to delayed HT. Peripheral monocytes are turning into macrophages 
and releasing MMP-9 and other inflammatory cytokines, maintaining 
the inflammation. During the monocyte infiltration they activate 
endothelial cells increasing their permeability. Microglia activation 
results in MMP-9 release. After augmentation of GM-CSF with rtPA in 
humans the incidence of HT did not increased, suggesting that maybe 
examination of different monocyte subtypes would be advantageous [2].
To assess the role of monocyte/macrophage infiltration, four 
different approaches were used and four groups of mice were formed: 
monocyte/macrophage depletion group, CCR2 inhibited, CCR2 
knockout and bone marrow chimera group. Recently 2 different types 
of monocyte subpopulation have been identified. The first group with 
high level of the CCR2 chemokine receptor and the Ly6c antigen but 
low levels of CX3CR1, while the second group is characterized by the 
absent of CCR2, low Ly6c, and high CX3CR1. The first group of cells 
infiltrates the brain tissue in acute inflammation, the second group 
patrols in non-inflamed tissue. According to the functional role above, 
the 2 types of macrophages are the M1 type, activated in classical way 
with role in the inflammatory response and M2 type with repairing 
potential, activated in alternative ways. This study showed a worse 
outcome in CCR2 pathway deficient mice with higher rate of HT 
on day 3 and 6, with a decreased TGF beta, collagen 4, SMAD2 level 
(pathway of TGF signaling), causing bleeding from the border zone 
from thin walled and dilatated neovessels, though when TGF beta was 
injected into the lesion border, the HT rate decreased. An inhibition 
of CCR2 with propagermanium or the monocyte/macrophage 
depletion model also ended in a higher rate of HT with the same TGF, 
SMAD, collagen 4 levels, showing the critical role of bone marrow-
derived CCR2+ monocytes/macrophages in maintaining integrity 
of the neurovascular unit after ischemic stroke. These data suggest 
that monocyte/macrophage subtypes has crucial effect in preventing 
secondary HT and promoting repair. These observations highlight the 
fact that therapeutic approaches should concentrate on modulating the 
macrophage function instead of inhibiting the monocyte recruitment. 
This study revealed, that TGF signaling, as critical part of the tissue 
repair, is monocyte/macrophage dependent, and that early CCR2-
dependent recruitment of peripheral inflammatory monocytes and 
their subsequent differentiation within the environment of the CNS 
lesion into non-inflammatory phagocytes is the connecting mechanism 
between post-ischemic inflammation and regeneration [146].
In contrast to that other studies on CCR2 pathway deficient mice 
state that CCR2 pathway has a harmful effect regarding the HT rate and 
outcome. In the deficient group of mice the infiltration of monocytes 
and neutrophils were lower, the BBB damage and the HT rate was 
decreased [147-149]. 
The following study was based on earlier promising results and 
aimed to extend the knowledge about influencing factors on MO/
MP activation, differentiation and polarization. The examined factors 
were hyperglycemia as a frequent co-morbidity in stroke patients 
and the peroxisome proliferator-activated receptor gamma (PPARγ) 
activation. Artificial hyperglycemia was induced by streptozotocin. 
Hyperglycemic and PPAR knockout mice showed a shift toward 
inflammatory MO/PO response with a consequent increased rate of 
secondary HT caused by abnormal, leaky, thin walled, dilated neovessel 
formation and rupture. Though pharmacological PPAR activation via 
pioglitazone resulted in a reduced HT rate, which was independent 
from hyperglycemia but hugely dependent on MO/MP presence. 
These results altogether suggest that the inflammatory and anti-
inflammatory-repair differentiation of macrophage subtypes basically 
determine the HT rate and therefore the clinical outcome. Interestingly 
PPAR modulation did influenced PH rate [150].
PPAR has influencing effect on neutrophil granulocytes as well. 
The supposed mechanism occurs after reperfusion as part of the early 
inflammatory answer. The inflammatory cells use glucose to be able to 
react quickly, but PPAR activation shift the energy usage toward fatty 
acid metabolism. Accordingly, it has effect on the cell metabolic activity, 
probably contributing to the inflammation weakening effect. PPAR 
has neuroprotective effect as well on several intracellular pathways, 
suggesting that PPAR take part in preventive mechanisms both in the first 
24 hours and also after that by regulating the neuroinflammation [151]. 
Like in any other part of the body, also in the CNS an inflammation 
goes along with COX-2 mediated PGE2 elevation. Both the knocking-out 
of prosaglandin EP1 receptor and the usage of EP1 receptor antagonist, 
SC-51089 after tMCAO was associated with significant lower HT rate 
and BBB disruption as a consequence of significant reduced MMP3 and 
MMP9 levels, lower degree of neutrophil infiltration, and higher ZO-1 
and occludin levels in the brain. This report proves an important link 
between neuroinflammation and BBB breakdown via MMPs. EP1 as 
a therapeutic target should be considered [152]. Further mechanisms, 
play in the neuroinflammation a considerable role as well.
Vascular remodeling 
Vascular remodeling is natural part of the recovery process in the 
infarcted tissue, but unfortunately at the same time it promotes HT as 
well. Neovascularisation takes place with the leading of VEGF, MMP 
and other growth factors. New vessels incorporate into already existing 
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vasculature, but these neovessels are weaker and leakier, predicting 
HT. In rodent, models suppression of hypoxia inducible factor 1 alpha 
resulted in the reduction of HT incidence. VEGF administration also 
in rodent studies within the 1 hour of stroke increased the severity of 
BBB disruption. However, when VEGF was given within 3-24 hours 
it reduced BBB permeability, increased pericyte coverage of brain 
capillary, enhanced angiogenesis and therefore increased cerebral 
blood flow and neurological recovery. Apparently, VEGF has biphasic 
role after stroke, and as expected, the recent observations show that 
MMP-9 has a biphasic role too. Early MMP inhibition cause reduced 
lesion size and increased TJ protein expression on endothelial cells 
and pericytes, implying a BBB protective effect, however delayed 
administration of MMP inhibitor in mice after 7 days from stroke 
onset, ended up in a suppressed remodeling and as a consequence in 
impaired functional recovery. Also angiopoetin seems to be involved 
in this process. Angiopoetin 1 is supposed to be associated with BBB 
disruption based on the fact that elevated serum level of angiopoetin 
1 predicts HT after rtPA treatment, and angiopoetin 2 is likely to be 
related to neovascularisation. A damage associated molecular pattern 
molecule called high mobility group box 1 (HMGB1) is released by 
astrocytes and acts on HMGB1 receptor on endothelial progenitor 
cells, promoting angiogenesis and shows association with better 
long term outcome [2]. The effect of extracellular HMGB1 on HT is 
presumed to happen via TLR4 mediated MMP-9 activation [153]. 
HMGB1 contributes even to the hyperglycemia enhanced worse 
clinical outcome and BBB disruption [83]. 
Effect of ROS on delayed HT 
ROS has a central role, not just in the early but in the delayed BBB 
breakdown as well. It has regulating effect on almost every known 
important pathways leading to BBB disruption, such as VEGF, hypoxia 
indictable factor 1 alpha, MMP activation, NFkB activity, protein 
kinase C activity, ERK1 and 2 activity, p38 MAP kinase activity. It 
participates in EPC (endothelial progenitor cell) mobilization, homing, 
differentiation, and as a result guides the whole angiogenesis and 
the vascular remodeling process. ROS stimulate endothelial cells to 
proliferate and migrate. Both in NOX1 and NOX2 (encode NADPH 
oxidase) knockout mice, the antigenic activity and neovascularisation 
were impaired [2]. 
SRC kinase 
Blood products getting out of vessels cause further damage in the 
ischemic area. To investigate the effect of thrombin in the brain tissue, 
experimentally thrombin was injected into the ventricle of rats, causing 
vascular leakage and brain edema at 24 hours [2]. Thrombin acts on 
protease activated receptors, like SRC kinase, causing phosphorylation 
cascade on NMDA receptors [154]. and causing neuronal death via 
calcium dysregulation, ending up in MMP and VEGF release and 
a consequent BBB opening. These processes were solved by the day 
14, giving space to a long term repairing effect by phosphorylating 
cell cycle genes. This statement is supported by the observation, that 
SRC family kinase (SFK) inhibitor co-administered with thrombin 
prevented the BBB opening, though SFK treatment on day 2-6 after 
thrombin injection inhibited the above mentioned long term positive 
effects of thrombin [2].
Imaging
The identification of patients, who has higher risk for HT is 
important before rtPA administration to possibly avoid PH-2, the 
most feared adverse effect of rtPA treatment. In the field of imaging, 
only the early ischemic sign on CT or MRI is used commonly for pre-
selection of patients, in spite of its poor sensitivity and reproducibility. 
Treatment indications based on MRI showed altogether lower risk for 
HT than those CT based. It is known that increased lesion volume on 
DWI and increased delay on PWI are associated with increased rate 
of HT. Severe delay on PWI was proven to be stronger factor for HT 
formation than tissue status on DWI, tested with GRE. Gradient-
recalled echo (GRE) has excellent specificity and sensitivity in 
visualizing intracerebral bleeding and was found at least as accurate as 
CT in detection of hemorrhage. GRE follow-up examination of stroke 
patients showed that HT type did not influence the NIHSS reduction 
in the first 7 days, moreover, deterioration in NIHSS was commonly 
observed during the early course of hospitalization regardless of the 
presence of HT. The relationship between radiological and clinical 
categories of HT was stronger in patients with milder on admission 
disabilities (initial NIHSS <14 points) than in patients with severe 
disabilities (>14 points) [49].
Some studies concentrate on early tissue status and subsequent 
HT, but others put emphasis on hypoperfusion MRI changes and 
subsequent HT with a result that implies, severe hypoperfusion 
on MRI (>8 sec) has bigger relevance in HT than DWI or early CT 
finding. rtPA administration should be considered in cases with 
severe hypoperfusion, regardless of the size of the core. Perfusion 
supporting interventions should be started not just for tissue salvation, 
but to decrease the HT risk, balancing with the fact, that aggressive 
recanalisation treatment is independently associated with HT [155].
Future therapeutic possibilities and protecting factors
Today unfortunately just 5% of all the patients suffering an 
ischemic stroke are eligible for rtPA administration, mostly because 
of the most feared adverse effect of rtPA, the HT. Unfortunately, the 
promising results in animal models in most cases are not translated 
into successful human trials due to the huge differences between 
animal models and the human body. At the time of this review rtPA 
remained the only approved treatment of stroke. None of the tried 
agents was be able to replace rtPA, but in case of co-administration 
some of them showed beneficial effect regarding the HT rate, also in 
human trials, such as minocycline, GM-CSF, uric acid or edaravone. 
As long as rtPA administration remains the only curative intervention, 
the aim of the future researches is the therapeutic window extension 
by preventing HT with the help of potential neuroprotective or BBB 
stabilizing agents. The better understanding of molecular underlying 
mechanisms helps to find always newer potential molecular targets 
to prevent HT, since to date none of them reached breakthrough in 
human trials. Probably the different molecular pathways in early and 
in delayed hemorrhage and thus the different molecular targets are 
standing in way of success. Some of the main targets so far have proved 
biphasic role, which means that early blocking of MMP-9, and ROS 
prevent HT, but at the same time the recovery processes are inhibited 
as well. Another approach of HT prevention is the proper preselection 
of patients for rtPA treatment, considering the individual risk factors 
[156]. 
Minocyclin
The molecular acting mechanism of minocycline, which is a 
broad-spectrum tetracycline antibiotic was investigated in mice, 
that had genetically induced cerebral amyloid angiopathy ending in 
hemorrhagic stroke. The minocycline hugely modified the MMP and 
inflammatory pathways in a positive way and connecting to that, 
higher levels of microvascular tight junction and basal lamina proteins 
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were found, proving its BBB protective effect, which could be utilized 
in ischemic stroke treatment, parallel to rtPA administration [157]. 
Furthermore, minocyclin was tested on spontaneous hypertensive rats 
as well. MMP-9 serum levels by 6 hours after stroke onset were lower, 
infarct size was smaller and HT rate was also lower, suggesting that 
minocycline is beneficial in extending the rtPA therapeutic window [158]. 
Minocycline was found to be potentially applicable in clinical 
usage. In this two, open-labeled evaluator-blinded trial 60, respectively 
50 patients were enrolled, both with the conclusion that the patient 
group, which received minocycline daily for 5 days after stroke onset 
had significantly better NIHSS scores on day-90 control, however 
female patients did not show this positive result [159,160].
Absence of a definitive target that is responsible for the effect of 
minocycline is preventing the further results. Caspase-1, caspase-3, 
cyclo-oxygenase-2, inducible nitric oxide synthase, p38 mitogen-
activated protein kinase, gelatinase, MMP-9 are supposed to participate 
in the molecular mechanism of minocycline [157,160].
Uric acid
Higher serum uric acid level was significantly associated with 
lower HT rate and better outcome among stroke patients with rtPA 
administration [121]. This recent meta analysis of 8131 acute ischemic 
stroke patients reports that high uric acid serum level on admission 
should be regarded as good prognostic marker, suggesting its positive 
impact on BBB damage. Uric acid as an endogen antioxidant is a 
promising therapeutic neuroprotective agent [161]. Based on promising 
animal studies human trials were begun. URICO-ICTUS, a double-
bind phase III study was designed to investigate the safety and efficacy 
of uric acid in the management of acute stroke. Unfortunately, it failed 
to provide the expected therapeutic success, because administration 
of uric acid in addition to rtPA did not increased the rate of excellent 
outcome. Though, uric acid administration was found to be safe, it 
increased neither mortality nor hemorrhagic event or gout [162]. 
Secondary reanalysis were proceeded in different subpopulations, and 
it turned out, that in the woman subpopulation and among patients 
with hyperglycemia during acute stroke the uric acid administration 
with rtPA raised the number of excellent outcome and increased infarct 
growth in comparison to placebo. Hyperglycemia greatly increases 
ROS burden, and uric acid - as an antioxidant - is supposed to perform 
its positive effect in the way of ROS neutralizing [163,164]. 
Edaravone
The human usage of this free radical scavenger was based on 
promising animal studies that reported that edaravone significantly 
attenuates infarct size and HT rate in hyperglycemic rats [165]. 
Further studies found that this agent performs its beneficial effects 
via MMP-9 inhibition as well [166]. Since 2001 in Japan, edaravone is 
an approved treatment of ischemic stroke when administered within 
the first 24 hours of onset. Human studies show that edaravone can 
significantly suppress MMP-9 serum level after ischemic stroke 
[167]. On the other hand, edaravone was found to increase the HT 
rate in case of cardiogenic embolism treated with heparin and rtPA, 
though this did not impact the clinical outcome, on the contrary, the 
group treated with edaravone showed a higher rate of good outcome 
among patients suffered HI-1 and HI-2. The higher rate of HT is the 
consequence of the observation that beside the neuroprotective and 
endothelprotectiv effect of edaravone, the agent interferes with the 
fibrinolytic and coagulation system. It highlights the known fact, that 
ROS inhibit fibrinolysis and coagulation; ergo edaravone could reduce 
both the rtPA and heparin dose, preventing the negative effects of rtPA. 
Edaravone reaches the ischemic lesion when HT occurs [168]. 
A recent retrospective study compared 356 patients treated with 
edaravone and rtPA at the same time and 356 patients treated just 
with thrombolysis. After a logistic regression analysis, it could be 
ascertained that edaravone administration was significantly associated 
with lower mRS score at discharge, implying that it may improve early 
clinical outcome [169].
Isoflurane as a common used anesthetic
The role of isoflurane in the modulation of ischemia-reperfusion 
process and in HT is rather controversial. The effects of isoflurane were 
investigated both in case of preconditioning and postconditioning. 
In case of isoflurane preconditioning in rat models, short and even 
long term neurological outcome was improved, and the supposed 
neuroprotective effect of isoflurane was rested upon Bcl-2 induction 
[170]. To this neuroprotective effect may contributes the Notch 
signaling pathway as a central route of the inflammatory response and 
neuronal progenitor cell proliferation, differentiation [171]. The further 
molecular mechanisms of the pre and postconditioning may include 
lower level of inflammatory cytokines, decreased MMP-9 activation 
and ROS induced lipid peroxidation and due to that decreased tight 
junction protein degradation [172]. In case of postconditioning, the 
transforming growth-beta 1 pathway upregulation along with the 
c-Jun N-terminal kinase signaling pathway downregulation, which is 
part of the repair process, participates in the supposed neuroprotective 
effect [173]. Also mitochondrial adenosine 5′-triphosphate-sensitive 
potassium channels are assumed to be involved in the positive effect 
of isoflurane [174]. Isoflurane postconditioning was found to be 
effective in decreasing the infarct volume and HT rate in rtPA treated 
ischemic stroke model, proving its potential as candidate in future 
stroke therapy [175]. Though, other studies found no neuroprotective 
effect after preconditioning in case of intracerebral hemorrhage 
[176]. Moreover, in hyperglycemic rat models, postconditioned with 
isoflurane after stroke, one study found directly negative impact 
regarding the neurogical deficit when compared to the control group, 
with no influence on infarct size, brain edema and HT volume. It 
was accompanied by increased oxidative stress, possibly induced by 
decreased superoxide dismutase and catalase expression [177]. 
Hydrogen gas inhalation 
For 2 hours after 90 minutes MCAO in hyperglycemic rat models 
was accompanied by decreased infarct size and HT rate and due to 
that improved neurological status. A remarkable aspect is, that 1 hour 
hydrogen inhalation did not decreased the infarct size but decreased 
HT rate, suggesting the direct effect of hydrogen on the HT process, 
independently from infarct size. The underlying mechanisms may 
include reduction of the expressions of 8OHG (nucleic acid oxidation 
marker), HNE and nitrotyrosine (markers of lipid peroxidation and 
protein nitrification), and the activity of MMP-9. However, the 
treatment had no significant impact on the decreased level of ZO-1, 
occludin, collagen IV in the brain, or on the increased expression of 
AQP4 which channel participates in the maintenance of BBB integrity 
and whose expression is increased in case of ischemia, suggesting that 
the prevention of HT in this study happened also in other ways beside 
MMP-9 inhibition or AQP4 downregulation [178]. 
Other agents administered with the purpose of ROS inhibition 
like spin-trap-agent NXY-059 [179] or N-t-Butyl-Phenylnitrone was 
ineffective. Further potential agents that are associated with lower 
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HT incidence in animal models are the followings: activated protein 
C, PDGFR alpha antagonists, cilostazol (phosphodiesterase inhibitor), 
melatonin, fasudil (rho kinase inhibitor), fingolimod (sphingosine 
1-phosphate receptor agonist), poly ADP ribose polymerase (PARP) 
inhibitors, sulfonylurea receptor 1 (Sur1) inhibitors (glyburide), 17-
beta estradiol, FK506 (tacrolimus), VEGF inhibition and hyperbaric 
oxygen [180]. Erythropoietin exacerbates rtPA-related HT [2]. 
TGF-ß 1
Administered TGF-ß 1 in addition to rtPA after 3 hour of MCAO 
in rats reduced the basal lamina degradation, the BBB disruption 
and so the HT rate. The supposed mechanism of acting includes 
inhibited rtPA induced MMP2 and MMP9 elevation and upregulated 
PAI-1 expression. These pathways seem to be protective against BBB 
breakdown in the early stage of stroke [181]. 
Tiazide
Long term use of tiazide seems to be associated with lower initial 
NIHSS and better 3-month mRS score [182]. The possible cause of 
this observation is that hydrochlorotiazid therapy restores the dilatory 
capacity of cerebral arterioles, improving the collateral supply, hence 
leading to smaller infarct volume and lower HT rate. The increased 
blood pressure in the acute phase of stoke has positive effects on 
maintaining the collateral flow. The break of a long term tiazide usage 
after stroke onset may contribute to a better cerebral blood flow by 
fluid retention, better blood viscosity. Based on these results, tiazide as 
first line antihypertensive drug would be good choice [183]. 
FeTMPyP
Co-administration of peroxynitrite decomposition catalyst (Fe(III)
tetrakis (1-methyl-4-pyridyl) porphyrin pentachlorideporphyrin 
pentachloride) to rtPA has beneficial effect on HT rate in rat models. 
The rtPA treatment after 5 hours of MCA occlusion caused severe HT, 
neurological deficit, MMP-9 and MMP-2 upregulation and elevated 
peroxynitrite level. Co-administered FeTMPyP prevented HT, reduced 
the peroxynitrite, MMP-9 and MMP-2 level likely due to the inhibition 
of the peroxynitrite induced MMP upregulation, furthermore 
improved neurological outcome [184]. 
Progesterone
A new era of the progesterone research was started when it got 
proved that progesterone is synthesized by neurons and glial cells as 
well, both in the central and peripheral nervous system, both in males 
and females [185], and has an assumed neuroprotective effect [186]. 
Since progesterone acts via a core binding protein and alters DNA 
transcription, its effect on neurons are accordingly diverse, like up-
regulating the GABA neurotransmitter, decreasing lipid peroxidation 
and oxidative stress by its antioxidant effect, limiting the expression of 
inflammatory cytokines and decreasing cellular apoptosis. All of these, 
mechanisms result in significantly smaller infarct volumes, smaller 
extension of edema and altogether better neurologic outcomes on 
rat models [187-189]. Other studies proved that progesterone and its 
metabolite allopregnanolone inhibit MMP and VEGF upregulation, 
contributing to BBB maintenance [186].
A recent study based on the reports above, assessed the effect 
of progesterone on rtPA induced HT in rat models. The results 
are promising. Progesterone treatment attenuated rtPA-induced 
hemorrhage, brain edema, BBB breakdown and leakage and infarct 
volume. The reported mortality rates were 7.14% respectively 
27.78% in the saline- and rtPA-treated groups, whereas no mortality 
was observed in case of rtPA and progesterone co-administration. 
Furthermore, the transendothelial electrical resistance (TEER) value, 
which is used to estimate the permeability of endothelial cells in 
vitro, was examined after hypoxia/reperfusion. Reduced TEER values 
indicate TJ disruption. rtPA administration decreased the TEER, 
whereas co-administered progesterone effectively protected the BBB 
integrity. The data supports the observation that increased level of 
MMP is accompanied by decreased level of occludin and claudin in the 
brain after hypoxia/perfusion and rtPA treatment [190]. 
VEGF is known to contribute to BBB breakdown in the acute phase of 
stroke by MMP upregulation and enhanced capillary permeability. The 
activation of VEGFR2 tyrosine kinase receptor through dimerization 
and phosphorylation leads to further activation of various intracellular 
pathways such as phospholipase C, protein kinase C, ERK1/2, and Src. 
Administration of anti-VEGF antibody inhibits the BBB breakdown 
[191]. Progesterone treatment significantly decreases the VEGF level in 
brain endothelial cell culture media as well. rtPA possibly contributes 
to the BBB disruption among others via VEGF upregulation, which 
seems to be preventable by progesterone administration [192].
DHA
Docosahexaenoic acid is an omega-3 essential fatty acid and one 
of the major easily obtainable long-chain polyunsaturated fatty acids 
(PUFAs) in the human diet. Neuroprotectin D1 (NPD-1) is a well-
studied neuroprotective agent, that is actually a metabolite of DHA 
[193]. NPD-1 is part of a key survival signaling that upregulates anti-
apoptotic and downregulates pro-apoptotic proteins, promoting 
neuronal survival in stress situation, and in addition it decreases 
the severity of the inflammatory response through downregulated 
inflammatory gene expression, decreased ROS burden, leukocyte 
adhesion and extravasation. Earlier studies report that in case of 
ischemic stroke long term intake of DHA or one time injection before 
stroke onset, eventually the administration after 3 hours of MCAO 
or direct infusion into the third ventricle after MCAO decreases the 
infarct size and improve the neurological outcome [194]. To assess 
the direct effect of DHA on HT, dextrose was injected 10 minutes 
before MCAO to induce hyperglycemia, reaching larger ischemic 
infarct size and more severe hemorrhage. DHA significantly decreased 
HT rate, most likely through BBB protection. Reduced erythrocyte 
extravasation, increased collagen IV amount and reduced expression 
of the intercellular adhesion molecule-1 (ICAM-1) was observed that 
was followed by maintained BBB integrity and decreased inflammatory 
response. 7 days neurological status was improved and infarct size was 
reduced up to 60% in comparison to the control group [195]. 
GM-CSF
Regarding the impact of GM-CSF on the HT process is still 
controversial. GM-CSF was found to be responsible for increased HT 
rate in rats when co-administered to rtPA. It provoked neutrophilia 
and MMP-9 induction [196]. In comparison, other in vitro and animal 
studies reported that GM-CSF has beneficial neuroprotective effect 
by reducing the infarct size and edema, blocking glutamate induced 
neurotoxicity and apoptosis, inhibiting neuroinflammation by 
decreasing IL-1 level. Furthermore GM-CSF activates endothelial cell 
migration and proliferation, mobilizes CD34+ progenitor cells from 
the bone marrow, contributing to angiogenesis and neovascularisation. 
This aspect suggests that endogen GM-CSF is part of neuroprotecion, 
BBB protection and delayed repair mechanisms. Comparing the effect 
of rtPA treatment with rtPA and GM-CSF co-administration on 
spontaneous hypertensive rats after temporary MCA occlusion show 
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that GM-CSF administration contributes to decreased HT rate - proved 
by decreased hemoglobin content in the brain tissue - and to decreased 
infarct size. rtPA plus GM-CSF administration was accompanied by 
higher CD34+ cell number in the ischemic hemisphere, higher Ang-
2 angiogenesis marker, vWF vasculogenesis marker and VEGF-2 
compared to the group treated just with rtPA. Ang-2 participates in 
the ischemia induced neovessel formation by increasing the capillary 
diameter, helping the remodeling of the basal lamina and the growth 
of new blood vessels [197]. CD34+ endothelial progenitor cells are 
known to participate in BBB repair after ischemia and their presence 
is connected to better functional outcome. Circulating CD34+ cells 
after stroke are assumed to predict the long term clinical outcome 
[198]. Intravenous transplantation of endothelial progenitor cells was 
associated with better long term functional outcome too by promoting 
BBB repair [199]. 
Indeed, human studies report altogether beneficial connection 
between GM-CSF and stroke outcome. A meta-analysis of 711 patients 
showed significant positive impact of the GM-CSF regarding the 
NIHSS and mRS score, along with increased CD34+ cell mobilization 
from the bone marrow [200]. The administration of GM-CSF seems to 
be safe and well tolerated, suggesting that GM-CSF would be a good 
candidate co-administered to rtPA for daily stroke treatment [201]. 
Wnt/β-catenin pathway
Previous studies revealed that a disturbed Wnt/β-catenin pathway 
contributes to BBB breakdown. This is a pathway, that controls cell 
differentiation and fate hence it is important in maintaining BBB 
integrity in stroke. Glycogen synthase kinase 3β (GSK-3β), as part of 
the adenomatous polyposis coli/axin/GSK-3β complex, is involved in 
the ubiquitination and proteasomal degradation of β-catenin which 
is the key molecule of the Wnt/β-catenin pathway. Inhibiting GSK-
3β with TWS119 is going to inhibit the degradation of β-catenin 
and therefore activate the Wnt/β-catenin signaling pathway. Indeed, 
using TWS119 parallel to rtPA had a significantly advantageous effect 
on the HT rate, infarct volume and brain edema. Modifying this 
pathway resulted in increased expression of claudin-3 and ZO-1, both 
are elemental part of the tight junction system however the detailed 
linking mechanism in this phenomenon remains unclear [202,203]. 
This pathway according to other reports also has role in the controlling 
of the neuroinflammation [204] and the angiogenesis [205]. 
Ang-1
Angiopoetin 1 is known to have a beneficial role in endothelial 
cell survival, vascular remodeling and in maintenance of the vascular 
stability, permeability. The mechanism of acting includes several 
ways such as VEGF pathway, stabilizing TJs, increasing glycocalyx in 
endothelial cells, shrinking intercellular spaces and altering the PDGF 
signaling pathway in pericytes. In addition, Ang-1 has neuroprotective 
effect as well. Its receptor, called Tie-2, can be found on endothelial 
cells, pericytes, and neuronal cells [206-211]. To assess the impact of 
Ang-1 on the HT process 4 different groups of rats were observed. The 
first group went through a permanent MCAO (HT rate: 17,4%), the 
second group got rtPA 1 hour after ischemia, so within the therapeutic 
window (HT rate: 6,7%), the third group got rtPA 4h after ischemia, 
so out of the time window (HT rate: 59%), and a control group. Ang1-
positive vessel density was investigated. In the second group, the density 
was not decreased compared to the control group but a significant 
decline was observed in the third group and to a lesser degree but also 
in the permanent MCAO group. This result implies that decreased 
endogenous Ang-1 expression may play a central role in HT that 
occurs when rtPA is administered out of the therapeutic time frame. 
After that, COMP-Ang1 protein (COMP=cartilage oligomeric matrix 
protein) was administered parallel to rtPA treatment, that suppressed 
the hemorrhagic transformation process and the cerebral edema as 
well, however had no effect on the infarct size, so the neuroprotective 
effect of Ang-1 was not proved, in comparison to earlier studies. Ang-1 
is a potential target for therapeutic BBB defense [212].
Apyrase
(APT102) Apyrase is a calcium-activated enzyme, which is naturally 
present in the human body, catalyzing the hydrolysis of ATP and ADP 
into AMP and inorganic phosphate. APT102 is a recombinant form of 
CD39 human apyrase. Apyrase was found to have an antithrombotic 
effect as a result of hydrolyzing extracellular ADP, inhibiting platelet 
aggregation with a minimally elevated risk for bleeding, because 
APT102 does not act direct on platelets, but in an indirect way via 
prothrombotic ways [156]. Apyrase has anti-inflammatory effect as 
well, reported in studies investigating the prevention of ischemia-
reperfusion injury after lung, myocardial and brain infarction [213-
215]. To assess the potential in APT102 in extending the time window 
of rtPA, aged rats were used to model the clinical conditions of the 
human population who suffer an ischemic stroke, since 72% of stroke 
patients are over the age of 65, and age is a strong risk factor of worse 
outcome, HT and stroke severity, as consequence of fragility of the 
BBB. 6 hours after MCAO rtPA and APT102 were co-administered. 
This combination was found to be significantly associated with 
decreased infarct volume, improved clinical outcome and prevention 
of HT, implying its beneficial effect in extending the time window 
till at least 6 hours from stroke onset. In case of endothelial injury 
or endothelial activation the local concentration of ATP and ADP 
increases, causing platelet activation, aggregation, fibrin deposition, 
worse regeneration circumstances and as a consequence microthrobus 
formation, hypoperfusion and just partial recanalisation. Inhibiting 
the endothelial activation prevents neutrophils from extravasation 
and that indirectly prevents MMP mediated BBB degradation. Thus 
APT102 requires reperfusion to perform its effect. These finding are in 
agreement with previous studies on CD39 knockout mice [216].
Hyperbaric oxygen preconditioning
It is known that hyperbaric oxygen preconditioning has 
neuroprotective effect via induction of the COX-2 enzyme during 
the preconditioning phase, that is followed by decreased level of this 
enzyme and its downstream targets in case of ischemia, extending 
the time window of neuronal survival. In addition, COX-2 inhibitor 
administration during the preconditioning phase eliminated the 
neuroprotective effect, proving the role of the COX-2 enzyme in 
hyperbaric oxygen preconditioning [217]. The presumed mediator of 
this phenomenon is the 15d-PGJ2 (15-deoxy-Δ12,14-prostaglandin 
J2), which is a modification of PGD2 by non-enzymatic dehydration. 
PGD2 is synthesized from arachidonic acid by COX-1 and COX-2, 
and PGD synthase. 15d-PGJ2 is an endogen ligand of PPARγ. It is 
a nuclear hormone receptor playing an extended regulating role in 
several cellular signaling mechanisms, such as apoptosis, oxidative 
stress and neuroinflammation. After the activation of PPARγ it forms a 
heterodimer with the PPAR-retinoid X receptor α (RXR) and binds to 
PPAR response elements in the promoter region of their target genes 
[218]. Earlier studies reported that activation of PPAR is associated with 
BBB prevention [219] and that hyperbaric oxygen preconditioning was 
accompanied by elevated 15d-PGJ2 and elevated PPARγ level [220]. 
15d-PGJ2 proved its neuroprotective effect via anti-inflammatory and 
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antioxidative ways in the following experiment. Hyperglycemic mice 
were investigated with 1 hour/day hyperbaric oxygen preconditioning 
for 5 consecutive days before MCA occlusion. 15d-PGJ2 and PPARγ 
levels were higher, along with lower serum levels of TNF-α and IL-
1β, ZO-1, occludin and lower activity of MMP-2, MMP-9. Altogether 
a significant better functional outcome and a lower rate of HT were 
observed in hyperglycemic MCAO rats after hyperbaric oxygen 
preconditioning. Administration of PPARγ inhibitor GW9662 
decreased the positive effect of preconditioning [221,222]. 
Further molecular pathways of HT prevention after hyperbaric 
oxygen preconditioning are assumed to involve Nod-like receptor 
protein 3 (NLRP3) inflammasome, which is a key component of the 
inflammatory response. It facilitates caspase-1 and interleukin-1β 
processing, in this way amplifying and maintaining the inflammatory 
response [223]. The activation cascade starts with excess level of ROS 
that oxidise thioredoxin into thioredoxin-interacting protein (TXNIP). 
TXNIP binds to NLRP3 causing its activation [224,225]. Based on 
the reports above hyperglycemic mice were undertaken a 1 hour 
hyperbaric oxygen therapy 5 days long before MCAO. The HT rate was 
significantly lower, though the infarct volume was unaltered. Different 
agents were administered to different groups of mice to investigate the 
steps of the signaling chain, such as thioredoxin-interacting protein 
small interfering RNA, Nod-like receptor protein 3 small interfering 
RNA and N-acetyl-l-cysteine as a general ROS scavenger. The NLRP3 
level was decreased after preconditioning and was increased after siRNA 
administration. The results suggest that the neuroprotective effect of 
the hyperbaric preconditioning involves the ROS/TXNIP/NLRP3 
pathway in hyperglycemic MCAO rats. The level of inflammatory 
molecules connected to the NLRP3 pathway such as interleukin-
1β, IL-6, and TNF-α after preconditioning followed by MCAO were 
decreased and after siRNA administration were increased. The MMP-9 
level altered in the same way suggesting that he BBB protective effect of 
preconditioning occurs through neuroinflammation inhibition as well 
[226]. 
SMTP
Approaching the problem of the HT from another point view, a 
new thrombolytic agent is now under investigation. A family of small 
molecules from the fungus Stachybotrys microspora was discovered 
which has a specific effect on plasminogen activation by modulating 
the conformation of the plasminogen molecule to be more susceptible 
to proteolytic activation. The most promising member of this family 
is the SMTP (Stachybotrys microspora triprenyl phenol). Since it 
is a plasminogen modulator, its effect depends on the endogenous 
plasminogen activator supply. Based on earlier rodent studies it has an 
assumed anti-inflammatory and neuroprotective effect too [227,228]. 
Studies on monkeys investigated the therapeutic potential of SMTP-7 
with the help of photoirradiation-induced endothelial injury followed 
by thrombotic MCA occlusion. As a conclusion SMTP-7 was found to 
be efficient in reducing cerebral infarct size and improved neurologic 
deficit as a result of recanalisation due to its thrombolytic effect. The 
thrombolytic efficacy is comparable to rtPA, but in addition SMTP-
7 decreased hemorrhagic transformation rate compared in the infarct 
area, compared to the vehicle control animal group. This observation 
is a consequence of the supposed anti-inflammatory effect. However 
further comparative studies between the rtPA and SMTP-7 are needed. 
As for the adverse haemostatic changes, no significant alternations 
following the SMTP-7 treatment (10 mg/kg) was observed in the 
heart rate, blood pressure, body temperature, blood gas and pH, 
haematocrit, blood glucose or in the activated partial thromboplastin 
time, fibrinogen, platelet aggregation, suggesting no involvement of 
hemodynamic changes or coagulation inhibition in the efficacy of 
SMTP-7 in the monkey stroke model. Only the fibrinolytic system 
was affected. SMTP-7 (10 mg/kg) also caused no significant changes 
in the fibrinolytic parameters such as plasminogen, a2-antiplasmin 
or D-dimer in the control monkey group, although, 2 times higher 
D-dimer level was observed referring to minimal mobilization of the 
fibrinolytic system. This result is in agreement with earlier studies 
on mice, where SMTP-7 did not increased the bleeding after tail 
amputation. The rtPA directly activates the plasminogen, though 
SMTP-7 acts in an on-demand way. The definitive advantage of SMTP-
7 against rtPA is that a therapeutic dose of SMTP-7 did just minimally 
affect the fibrinolytic system; however a higher dose of SMTP-7 was 
significantly associated with bleeding complications [229].
Roziglitazone
Thiazolidinediones as insulin sensitizing agents, activate nuclear 
receptor peroxisome proliferator-activated receptor gamma (PPAR-γ). 
It was proven that PPAR-γ has a dramatically positive effect on infarct 
size, HT rate and neurological outcome. The underlying mechanism 
is assumed to be the decreased expression of inflammatory mediators, 
such as IL-1, cyclooxygenase-2, inducible nitric oxide synthase [230]. 
Further mechanisms of suppressing the inflammatory response are 
involved as well [231]. Rosiglitazone improved neurobehavioral 
outcome, reduced infarct volume and hemorrhagic transformation 
rate, inhibited hemoglobin leakage [232]. The efficacy was unchanged 
in case of administration before, at the time or after ischemia in rat 
MCAO model. The mechanism behind this phenomenon is assumed to 
be the inhibited collagen IV level decrease in the brain due to elevated 
GLUT-1 expression [233]. Decreased level of GLUT-1 receptor was 
observed on endothelium surface in case of ischemia contributing to 
BBB disruption. Rosiglitazone did not perform its effect by decreasing 
serum glucose level, because serum glucose levels remained unaltered. 
The glucose decreasing effect needs time to emerge [234].
Hypercholesterinaemia
Hypercholesterinaemia and statin treatment as proof of earlier 
hypercholesterinaemia, was found to be potential neuroprotective, 
most likely due to its antioxidant effect. Hypercholesterinaemia was 
associated altogether with better clinical recovery rate [235-237]. 
According to a meta-analysis all type of HT was associated with 
lower LDL cholesterol level, furthermore, symptomatic HT showed a 
connection with lower total cholesterol levels as well  [238-253]. 
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